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I. INTRODUCTION 
1 
In its fundamental aspects, body physiology may be looked upon as a 
balanced mechanism of a series of biochemical and physico-chemical reactions 
which give rise to the observed physical or chemical changes. Far a study 
of this intricate physico-chemical s.ystem we need the appropriate physical 
and chemical "tools" through which we lllBY approach it at the level of 
fundamental processes. Pharmacological agents, i.e. natural or synthetic 
chemical compounds with potent biological effects, have been used re-
peated:cy, as chemical tools, in the elucidation of physiol.ogical problems. 
The present study describes certain attempts to develop such a pharma-
cological tool which may be used in the study of an old physiological 
problem, i.e. the possible physiological role of the natural~ occurring 
and biologically highly active amine, beta-aminoethyl-imidazoline (histamine) • 
Histamine is a potent biological substance having strong pharma-
cological effects on smooth muscle and secretory cells. Since its dis-
cCNery and the demonstration of its presence in manmalian tissues, numerous 
attempts have been made to find a physiological function for this amine 
but without ai\1 convincing success. Histamine is apparently released 
from the tissues urrler certain conditions , as during anaphylactic shock 
but its exact role in body economy under such conditions is entirely 
obscure. Similarly, it is not known whether histamine is continously 
released in the circulation subserving a specific function, although some 
authors feel that it may act as the hormone of gastric secretion. In 
general, the nearly universal occurrence of histamine and the multiplicity 
and potency of its pharmacological effects suggest that this amine may 
be involved in some fundamental way in body fUnction. 
2 
Experimental studies have shown that injected histamine is rapidly 
inactivated in the body. These support the observation that the pharma-
cological effects of this amine are often exceedingly fleeting. 
It has been suggested that the enzyme "histaminase", first studied 
by Best and McHenry (1930), is responsible for the inactivation of hista-
mine in vivo. Experimental proof of this early suggestion has been presented 
recently by the~~ studies of Sch~er and associates (1952-1954). 
The discovery of histaminase soon suggested the possibility that 
this enzyme m~ be used as a route of approach in the elucidation of the 
function of histamine. However, the question of whether histaminase is 
involved as the first step in the biological inactivation of histamine 
has never been answered. Therefore , it is not known whether histaminase 
actually plays a limiting role in the pharmacological or physiological 
responses to histamine. Yet, the insensitivity of certain tissues and 
species to this amine has been attributed often to the activity of hista-
minase although direct experimental proof is lacking. 
In short, it is not known whether histaminase is strictly a general 
metabolic enzyme ar possibly an enzyme involved s pecifically in the 
inactivation of a physiologically active substance, in a manner analogous 
to the inactivation of acetylcholine by cholinesterase. If the latter 
is true, then compounds with the ability to inhibit this enzyme would be 
most desirable 11tools11 in the study of the possible physiological role 
of histamine, as they would provide a new means of approach to this old 
problem. Such canpounds could be used in a manner similar to that which 
permitted the elucidation of the important role of acetylcholine by the 
discovery and use of cholinesterase inhibitors. 
3 
Early enzymological studies have established that a variety of chemical 
compounds act as inhibitors of histaminase under in vitro conditions. 
:r<!ore recent evidence suggests that they may have a similar influence on 
hi stamine catabolism in vivo. Until very recently, there were no reports 
of aqy attempts to potentiate the pharmacological effects of histamine 
by the use of these compounds. While our studies were in progress, a 
few such reports were published and these will be reviewed subsequently. 
It was the purpose of the present series of investigations to inquire 
into the possible influence of compounds, with known histaminase inhibitory 
activity in vitro, on several pharmacological effects of histamine, in 
an attempt to provide experimental evidence toward the answer of the 
following questions: 
a) Do such compounis potentiate pharmacological responses to histamine? 
b) Is such a potentiation related to the compound 1 s ability to inhibit 
histaminase? 
c) How do such canpounds compare in regard to their specificity and potency? 
An answer to the first two questions would indicate whether hista-
minase plays a limiting role in the pharmacological responses to histamine; 
it would also suggest whether the insensitivity of certain tissues and 
species to this amine is related to histaminase activity. 
An answer to the third question would be expected to provide infor-
mation concerning the relative usefulness of some of these compounds as 
investigational tools. 
II. LITERATURE REVIEW 
A. Histamine Metabolism 
1. Origin or tissue histamine: 
The demonstration of histamine in mammalian tissues, particularly 
in lungs, liver, skin and intestines (Rose 1947), raises the question of 
the site or formation of this substance. Two main possibilities may be 
considered in this connection. 
Firstly, tissue histamine may be or exogenous origin, i.e. absorbed 
fran the intestinal tract and distributed to the body tissues. Considering 
the nearly universal presence of histamine in an:ilnals and plants (Barger 
and Dale 1910) a considerable amount of exogenous histamine may be derived 
from ingested foods. Another portion of exogenous histamine is undoubtedly 
formed by the metabolism of intestinal bacteria particularly by decarboxyla-
tion or dietary histidine through the action or the en~me histidine de-
carboxylase. This enzyme is present in various species of normal intestinal 
bacterial flora. 
Secondly, tissue histamine may be or endogenous origin formed in~· 
The presence or histidine decarboxylase in various mammalian tissues and 
particularly in liver, kidney and intestine (Schales 1951) strongly suggests 
this possibility. In mammalian species whose dietary requirements have 
been studied, endogenous histamine must be derived from dietary histidine 
since in these species at least the organism is unable to synthesize the 
imidazole ring (Albanese 1950). 
The availability or radioactive carbon ( Cl4) made it possible to 
distinguish between exogenous and endogenous histamine. By incorporating 
this element at the C2 position or the imidazole ring, Schayer (1952b) 
was able to show that, after injection of small amounts of radioactive 
histidine in guinea pigs, a portion of the radioactivity was incorporated 
into the tissues as histamine and remained for many dqs. In contrast, 
following injections of small amounts of radioactive histamine, none of 
it could be detected in tissues after 4 hours. 
Schqer' s findings are in agreement with previously available indirect 
evidence in which it was shown that following large doses of histamine 
in the rat the level of tissue histamine rose temporarily but fell rapidly 
(within 3 hrs.) to basal levels (Rose and Browne 1938). 
These results, if repeated in other species, would suggest that 
tissue histamine is almost entirely of endogenous origin. 
2. Histamine databolism 
The pharmacological effects of small doses of histamine are generally 
of short duration and often exceedingly fleeting. Following injections 
of histamine in various species of animals, there is a rapid disappearance 
of histamine from the circulating blood (Waters 1950). It seems therefore 
that injected histamine is rapidly inactivated in the animal body. Under 
these conditions the inactivation m~ not be in the form of degradation 
of the histamine molecule but perhaps in the form of biological inactivation 
due to binding by same body constituents. Chemically, histamine is 
strongly basic, and binding with protein anions at body pH to form complexes 
with low dissociation constants is entirely possible fran a chemical 
point of view. 
Experimental evidence lends support to this view of histamine binding 
as a first step in the ·process of histamine inactivation by the animal 
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body {Rose and Browne 1938; Rocha e Silva 1944). Tlms certain workers 
have shown that when histamine is added to the blood or plasma in vitro 
a certain portion of it is quickly rendered physiologically inactive. 
This portion can be subsequently recovered by the usual extraction methods 
for histamine which involve protein precipitation by strong acids (Anrep 
et al. 1939; Parrot et a1.1953). 
It is then possible that body tissues have the ability to bini hista-
mine at a rapid rate and tlms render it biologically inactive. Unfortunately 
this phenomenon of histamine binding has not been studied extensively and 
its quantitative aspects are largely unknown. One may look upon histamine 
binding as an equilibrium condition in which only a portion of histamine 
is in the free form. Yet, the factors involved in determining the physico-
chemical parameters of this equilibrium are entirely unknown. Similarly, 
it is not known whether any alteration of these factors plays any role 
in pathological disorders in which histamine has been implicated. In 
fact the factual information on histamine binding in vivo is only fragmentary. 
While histamine binding may be involved in the immediate inactivation 
of histamine, the over-all catabolism of the amine must proceed through 
other pathways. A general picture of histamine catabolism may be obtained 
from the studies of Schayer and associates with radioactive histamine. 
Schayer (1952a) reported that when small doses (0.1 mg./Kg.) of 
radioactive histamine (labelled at C2) were injected in guinea pigs, rats 
or mice, 95-91% of the radioactivity could be recovered from the urine 
within 20 to 24 hours. Of this only a small per cent (depending on species) 
was in the form of free histamine. These results suggest that most of 
the injected histamine is rapidly metabolized and that all the metabolic 
7 
products containing the C2 of the imidazole rings are excreted in the urine. 
Through the use of chromatograms it could be shown that the urinary 
metabolites of injected radioactive histamine could be separated into 
three distinct peaks of radioactivity suggesting the presence of at least 
three forms of excretory products in histamine metabolism. One of these 
peaks was identified as due to free histarnine together with a small portion 
of acetyl histamine. The compounds or groups of compounds giving rise 
to the other two radioactivity peaks were not identified. 
FollovJing injections of radioactive histamine all three radioactive 
peaks ,,rere present in the urine of all species studied by Schayer (1952a, 
1953) i.e. the rat, the mouse, the guinea pig, and the cat (kittens 3-4 
weeks old). The relative magnitude of the three peaks was nevertheless 
characteristic of the species. 
Thus in the rat, about So% of the excreted radioactivity is associated 
with peak 1 (metabolite A), about 5% with peak 2 (metabolite B) and about 
15% with peak 3 (10% free histamine and 5% acetyl histamine). 
In the mouse, about 15% of the radioactivity is associated with 
metabolite A, about 45% vJith metabolite B, and about 3o% is mostly in the 
form of free histamine. 
In the guinea ~, metabolite A accounts for about 5o% of the radio-
activity, metabolite B 35%, free histamine 10% and acetyl histarr~ne 5%. 
In the cat (3-4 week old kittens), only 5% of the radioactivity is 
in the form of metabolite A, about 85% as metabolite B and lo% as free 
or acetylated histamine. 
The above quoted values are only rough estimates. Nevertheless, it 
may be safely concluded that in all species studied the major part of the 
8 
injected histamine is excreted in the urine within 20-24 hours. Thus 
histamine catabolism, following initial binding, proceeds through at least 
three main metabolic pathways, the metabolic products of which appear in 
the urine along with small amounts of histamine which is excreted in the 
free form. The excretory products then are: 
1. Free histamine 
2. Acetyl histamine 
3. Histamine metabolite A (peak 1) 
4. Histamine metabolite B (peak 2) 
In most species the amount of free histamine and acetyl histamine 
is very small (lo-1.5%), most of which is in the form of free histamine. 
The major part of catabolized histamine appears in the form of unidentified 
histamine metabolites A and B. 
The above conclusions are in agreement with earlier studies in which 
it was fourrl that following injection or oral administration of histamine 
in various species (including man), only a small portion of the amine is 
excreted in the free ar acetylated form; the majar part of it is metabolized 
(Anrep !!: al. 1944; Adam 19.50). 
The problem of acetylation of histamine has been studied by a number 
of workers. In the earlier literature, this compound is referred to as 
"conjugated histamine". From recent studies, it appears that histamine 
is acetylated in the intestine by the action of intestinal bacteria as 
well as in the animal body. The liver seems to play the major role in 
histamine acetylation in mammals (Tabar and Mosettig 1949; Urbach 1949; 
Millican et al. 1949; Wilson 1954a and 1954b) • 
9 
It is ~ggested by Lipnann (19.54) that acetylation of histamine is 
· a low energy reaction in which low energy acetyl Co-enzyme A acts as the 
i.tnmediate acetyl donor. In this respect the acetylation of histamine is 
qualitatively similar to the well known acetylation of sulfonamides. 
Similarly, acetyl histamine is pharmacologically inactive. 
The catabolism of injected histamine as outlined above might be 
expected to be qualitatively similar to the catabolism of endogenous 
histamine when it is released from the tissues. Recent studies on the 
catabolism of histaxnine liberated by the histamine liberator, compoum 
48/80 (Schayer 19.54) indicate that this view is in all probability correct. 
In contrast, the metabolic turn-over of endogenous histamine in the 
tissues, under normal conditions, is relatively slow. It has been 
established that the half-life of endogenous histamine in the guinea pig 
is of the order of 50 days. This estimate was based on measurements of 
the rate of disappearance of radioactive histamine from the tissues of 
animals injected with radioactive hist';.line (Schayer 1953). 
B. Histaminase: 
1. In vitro studies: 
Nature: Best ( 1929) first reported the disappearance of histamine 
when incubated with autolysing lung tissue at 37°C. in the presence ~£ 
oxygen. In 1930 Best and McHenry studied this phenomenon :further and 
attributed it to an enzyme system which they called histaminase. Latelj 
Zeller (1938) reported that an enzyme extract from hog kidney oxidized 
histamine as well as other diamines (particularly shorl chain alkyl· 
compounds) such as ethylenediamine, cadaverine and putrescine. He 
10 
proposed the names of diamine oxidase for this enzyme. Experiments w.i.th 
various diamine oxidase preparations, made from several tissues by, ·Zeller 
and others, shovmd that different preparations had the same ratio of 
activities on histamine as compared with other straight chain diarnines. 
On the basis of this evidence ~~y authors believe that histaminase or 
diamine oxidase is the same enzyme system (Zeller 1951; Tabor 1951). 
Of the two names they prefer "diamine oxidase 11 since it is descriptive 
in a more general way. 
The studies of Kapeller-Adler (1949) threw some doubt on the view 
of the identity of histaminase in regard to diamine oxidase, as she 
succeeded in obtaining preparations with different ratios of activities 
on histamine as compared to cadaverine. 
In the present thesis the name histawinase has been adapted as it 
is more descriptive of the enzyme involved in the enzymatic degradation 
of histamine in the animal body. 
Zeller identified flavin as part of histaminase (diamine oxidase) 
and therefore considers it to be a flavoprotein (Zeller 1951). Laskowski 
et al. (1945) were unable to confirm this. According to Kapeller-Adler 
(1949) histaminase but not diamine oxidase possesses flavin adenine 
dinucleotide (FAD) as a prosthetic group. This author believes therefore 
that histaminase is a flavoprotein and t his distinguishes it from 11diamine 
oxidase" which is not. 
This inhibition of histaminase qy carbonyl reagents (to be discussed 
in another section) strongly suggests that the enzyme possesses a carbonyl 
reactive group. This in turn gave rise to the early suggestion that 
pyridoxal may be an active prosthetic group of histaminase. The suggestion 
11 
was made by comparison vdth other known pyridoxal enzymeS(e.g. amino 
acid decarboxylase) which were also inhibited by carbonyl reagents. This 
possibility was not substantiated by experimental evidence in the case 
of histaminase (Sinclair 1952). 
Hechanism of action: Early studies w.i. th relatively i mpure preparations 
gave many contradictory findings regarding the steps in the histamine-
histaminase reaction. The extensive studies of Zeller (1938-1942), of 
Kapeller-Adler (1949), as "toTell as the more recent findings of Tabor (1951) 
suggest that the over-all reaction in vitro is as follows: 
Histaminase 
N NH 
NV NH 
Theore t ically for each mole of histamine oxidized one mole of oxygen 
should be consumed and one mole of H2o2 fonned. In the presence of 
catalase hov1ever, H2o2 decomposes to oxygen and water thus liberating 
o.5 mole of oxygen per mole of substrate. The early preparations of 
histaminase contained catalase. In more recent preparations (Tabor 1951) 
which were essentially free of catalase the theoretical oxygen uptake 
12 
(i.e. 1.0 mole of substrate) was approached. Ammonia and aldehyde deter-
~inations support this view. 
The resulting aldehyde (ind.dazole aldehyde) is further oxidized by 
either a dehydrogenase (e.g. aldehyde oxidase in the presence of DPN) 
or by an oxidase (e.g. xanthine oxidase in the presence of oxygen). The 
end products of the former reaction are imidazole acetic acid and reduced 
DPN. Imidazole acetic acid and more H2o2 appear as the products of the 
latter reaction in the presence of xanthine oxidase. 
The above findings constitute a well substantiated body of experi-
mental evidence regarding the action of histaminase in vitro. Yet, many 
--
experimental findin gs on the histamine-histaminase reaction in vitro defy 
any critical evaluation due to the variety of experimental methods used 
by different investigators. Thus interpretations of many in vitro 
enzymological studies have a limited value from a biological poiht of 
view. A swnmary of the various methods used in in vitro studies of 
histaminase is given below. 
Source of the en~e: Few workers used various tissues of common 
laboratory animals as a source of the enzyme. Most of the major investi-
gations were made utilizing hog kidney as the source of histaminase, because 
of its high content. In view of some recent evidence (to be discussed 
below) that there may be certain qualitative species and/or tissue differ-
ences in the enzyme systems involved in histamine inactivation in vivo, 
in vitro results using enzymes from different tissues may not be entirely 
comparable. 
Method of preparation of the enzyme: Most investigators used semi-
purified acetone extracts of the above mentioned tissues (and particularly 
13 
of hog kidney) as a source of the enzyme. A few studies were made with 
the whole tissues in minced form. In even fewer cases enzyme preparations 
of relatively high purity were used but .even then the methods and degree 
of purification varied among workers. 
Substrate: Histamine has been used as the substrate in a number of 
studies. Very extensive enzymatic studies however, have been carried out 
by using cadaverine or any of the other short chain alkyldiamines as the 
substrate. As already pointed out the identity of histaminase to diamine 
oxidase is not equivocal. It is therefore difficult to interpret results 
obtained with substrates other than histamine. 
Measuring enzymatic activity: For this, the rate of inactivation 
of biologically active histamine would appear to provide the most direct 
approach in connection w.i th the importance of this enzyme system in the 
metabolism of histamine. Only a few workers have used this approach in 
measuring the activity of histaminase preparations in vitro. Most often 
the oxygen consumption or ammonia production is taken as a measure of the 
activity. Among these indirect methods, measuring oxygen consumption 
seems to be the more inferior since it may be influenced by a variety of 
factors other than histaminase activity per se*. An even more indirect 
and less reliable method has been employed in which the enzymatic activity 
is measured in terms of the degree of decoloration of indigo disulfonate 
presumably due to the intermediate formation of H 0 • 2 2 
In general all of the many combinations of the above choices in the 
source of enzyme, type of substrate, and method of measuring activity 
* For example Born (1953) found that Cu++ potentiated the oxygen consump-
tion in such a reaction mixture While the rate of inactivation of bio-
logically active histamine remained unchanged. 
have been used by various workers. 
Histaminase units: Several "units" of histaminase activity have 
been proposed by various workers. Best and McHenr.y (1930) suggested as 
unit activity "that amount of activity which would destroy 1 mg. of 
histamine in 24 hours at 37°C. in a phosphate buffer at pH 7". Other 
units have been based on the rate of oxygen consumption, or ammonia 
production. The magnitude of these other units relative to that of Best 
and McHenry i s tabulated beloT-1: 
Units proposed by: 
Laskowski 
Zeller 
Stephenson 
11Torantil11 
Equivalent Best and HcHenry Units 
14 
2.6 
1.4 
o •. 58 
Specificity: All histaminase preparations made to date, in addition 
to their ability to oxidize histamine, will oxidize other basic diamines 
as well. In fact the available data indicate that most basic diamines, 
euanidines, and diguanidines have an affini ty for the enzyme and some act 
mainly as substrates while others act mainly as competitive inhibitors. 
Kapeller-Adler (1949) has stated that certain potent histaminase 
preparations exhibited a greater affinity for histamine than other diamines. 
Zeller (1951) however maintains that all enzyme preparations made by his 
group show highest affinity for the aliphatic diamine cadaverine. In the 
series of aliphatic di~ines of the general formula: 
NH2.(CH2)n.NH2 
Compounds n2 to nl4 are substrates of the enzyme, while nl4 to nl8 act 
15 
only as competitive inhibitors. The reaction velocity (and presumably 
the affinity) in this series of compounds , is progressively increasing 
between n2 and n5 where it reaches a maximum and it is then progressively 
decreasing between n5 to nl4 (Blaschko and Hawkins 1950). Cadaverine 
is t he n5 compound. 
2. The role of histaminase in vivo 
Several lines of evidence suggest that this enzyme pl~s a definite 
role in the metabolism of histamine in vivo. 
----
Mahler et al. (1952) isolated imidazole acetic acid from the urine 
of rats following large intraperitoneal doses of histamine (16.5 mg./100 gms.). 
As indicated above, imidazole acetic acid is a product of the histamine-
histaminase reaction ~~ vitro. 
Using an in vivo radioactivity dilution technique, Tabor~ a1. 
(1953) were able to show that imidazole acetic acid is fonned in the rat 
following small doses of radioactive histamine. Under such conditions 
the small amount of imidazole acetic aeid formed is further metabolized 
before excretion. These findings were in agreement with previous results 
of Schayer (1952c) who found less than 2% imidazole acetic acid in the 
urine of rats injected with small doses of histamine (O.Olmg./100 gms. i.v.). 
The above studies provided the first direct evidence that, in the rat, 
histaminase m~ be involved in histamine metabolism in vivo. It was then 
estimated that in this species following small doses of histamine, a 
maximum of 4o% of the injected amount was converted to imidazole acetic 
acid before further degradation. 
More recently Schayer and associates (1953a, 1953b) found in the 
16 
rat t hat , f ollowing small doses of radioactive histandne (O.Ol5-0.0l8 mg./ 
100 gms. i. v.), the peak of the urinary metabolite A -v;ras markedly repressed, 
when the animals were pretreated with diamine oxidase inhibitors. In 
these urinary chromatograms there was no change in the peak of metabolite 
B while the peak of free and acetyl histamine was increased in proportion 
to the decrease in the peak of metabolite A. 
Similar depression of the peak of metabolite A by diamine oxidase 
inhibitors 
ldttens). 
was obtained in urinaz-.r chromatograms of other species (mice, 
Furthermore these inhibitors were found to inhibit the oxidation } 
of injected cadaverine in vivo in both mice and rats (Schayer ~ al. 1954) 
which gives additional support to the postulated nature of inhibiton. 
It is t herefore tentatively concluded that the urinary metabolite 
A following injections of histamine, represents one or more products due 
to the action of histaminase on histamine. Metabolite B on the other hand, 
represents a metabolic product which apparently does not depend on the 
activity either of histaminase or of any other enzyme system which is 
inhibited by diamine oxidase inhibitors. 
In connection "I>r.i th the above conclusions, a comparison of the relative 
magnitudes of the urinary histamine metabolites in different specie s . 
shows that the importance of histaminase in histamine metabolism varies 
with the species. Thus, in the rat, this metabolic pathway is of primary 
importance. In the guinea pig this pathway is of relative importance, 
while in the mouse and especially in the cat it is rather insignificant. 
Occurrence: Histaminolytic activity is found in some higher plants, 
certain bacteria and in the tissues of reptiles, birds and mammals. Among 
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plants Atropa belladona (Cromwell 1943) as well as certain other species 
(vJerle et al. 1944) have been reported as possessing histaminase-like 
activity. 
Although no S'IJStematic studies have ever been made on the occurrence 
of histaminase in bacteria, sporadic reports suggest that the enzyme has 
a wide distribution among bacterial species (Zeller 1951). Specific studies 
have established the presence of histaminase in Pseudomonas pyocyanea 
(Gale 1942) as well as in Mycobacterium smegmantis and possibly in other 
Mycobacterium species (Zeller et al. 1951). 
In animal tissues histaminase is generally found in kidney, intestinal 
mucosa, liver and lungs, in order of diminishing activity (Best and McHenry 
1930; Zeller 1951; ~Tilson 1954). In birds and reptiles, however, hista-
minase is in higher concentration in the liver than in the kidney. Again, 
the white rat and other rodents have only small amounts of histaminase 
in the kidney . 
Considerable amounts of histaminase are present in the mammary and 
the prostate glands. The blood and brain usual1y contain little or no 
histaw~nase (Zeller 1951). 
The placenta of certain species (man, rat) contains large quantities 
of histaminase. To this is att ributed the increase in blood histaminase 
in advanced pregnancy (Danforth 1939; Kapeller-Adler 1951; F~berts 1954). 
In the dog the intestine and kidney have the highest content of 
histaminase. The enzyme is apparently in equal concentrations in duo-
denum, jejunum and caecum. No detectable amounts are present in stomach 
(Best and McHenry 1930; Zeller 1942). 
In the cat high concentrations of histaminase are present in the 
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small intestine and kidney. Gastric mucosa has no detectable amounts. 
In some cases very small amounts are found in the pyloric region. The 
histaminase content is highest in the small intestine. It is found in 
rapidly diminishing concentrations in the caecum, colon and recttw. 
Generally, the enzyme is present in the intestinal mucosa; separated 
intestinal muscle layers contain 2 to lo% of the total (Haeger and 
Kahlson 1952). 
An increase in the histaminase content of the lymph has been 
reported following adrenalectomy or adrenal hypofunction in cats. This 
appears to be related to a concurrently developing decrease in tissue 
histaminase in the adrenalectomized animal (Carlstein 1950; Haeger et ~· 
1952). Similarly, a reduced abilit,y of the tissues to destroy histamine 
appears to occur following adrenalectomy in the rat (Rose and Browne 
1940; Karady et al. 1940). 
c. Histaminase Inhibitors: 
A variety of compounds have been described as having anti-histaminase 
activity in vitro. By eliminating those compounds whose actions seem to 
be largely non-specific (such as compounds knmm to be inhibitors of 
oxidation or of enzymes in general), histaminase inhibitors can be class-
ified into two main groups• 
1. Carbonyl reagents 
2. Histaminase substrates or compounds having structural similarities 
to these substrates. 
Later an attempt will be made to show that the action of both groups 
of compounds may be essentially the same. 
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1. Carbonyl reagents 
Certain monoalkyl derivatives of ammonia, i.e. arnines of the general 
formula R. NH2 are known to condense with carbonyl groups (i.e. aldehydes 
and ketones) forming stable compounds. This property is of ten utilized 
in organic chewistry to obtain crystaline products of many aldehydes 
and ketones in the form of carbonyl reagent derivatives. 
\r?ell knmm carbonyl reagents are: 
1. Dimedonel~ 4. Phenylhydrazine 
2. Hydrazine 5. Semicarbazide 
3. Hydroxylamine 6. Thiosemicarbazide 
All of these compounds have been found to be s trong inhibitors of 
histaminase in vitro. The inhibitory potency varies. All of them show 
some activity in concentration of 0.01 mM/1. Quantitative results on 
their relative activities as inhibitors of histaminase with histamine 
as substrate are entirely lacking. Schuler (1952), using hog kidney 
histaminase with cadaverine as substrate, and me asuring oxygen consumption 
found: hydrazine;> semicarbazide) thioseffiicarbazide in their ability 
to inhibit histaminase. Hydrazine caused maximal inhibition at con-
centrations of 0.01 mM/1; semicarbazide was 10 times and thiosemicarbazide 
100 times less active than hydrazine. 
Certain deri va.ti ves of the above compounds1 which may also act as 
carbonyl reagents have been reported as pos sessing histaminase inhibitory 
activity. Thus Gro ss et al. (1952) found that a number of hydrazino-
phthalazines possessed such an activity. These compounds gave 5o% 
* Dimethylcyclohexadione 
inhibition in concentration of 1.5 to 8.0 mM/1. 
Two other derivatives of hydrazine have been reported to inhibit 
his t aminase in vitro and possibly in vivo. They are the recently 
developed anti-tubercule~ agents: 
l. Iproniazid- 1-isonicotinyl-2-isopropyl hydrazine (IIH or 
Marsilid). 
2. Isoniazid- Isonicotinic acid hydrazide (INH, Rimifron). 
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Zeller et al. (1952) reported that both possess histaminase inhibitory 
activity in vitro. Isoniazid was found to be a stronger inhibitor of 
histaminase than iproniazid. The l a tter was found to be an inhibitor of 
liver amine oxidase, an activity which isoniazid does not possess. 
Isoniazid is said to be an active histaminase inhibitor in concentrations 
pf 0.25 mM/1. 
2. Histaminase substrates and competitive inhibitors 
Compounds with a certain affinity for histaminase may act as sub-
strates or as competitive inhibitors. Such groups of compounds are: 
1. Aliphatic diamines 4. Monoamines 
2. Substituted diamines 5. Polyamines 
J. Imidazole and derivatives 
As previously stated alkylitamines may serve as substrates or inhibitors. 
In general, short chain compounds are substrates while long chain compounds 
act as competitive inhibitors (Blaschke and Hawkins 1950). Among diamine 
derivatives when one of the amino radicals is substituted the compound is 
still a substrate of the enzyme. Such can be considered the case of 
histamine and agmantine. 
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If both amino radicals are substituted the compound is a strong 
inhibitor. Thiamine, pyridoxamine, piperazine and several diguanidines 
apparently belong to this group. They are reported to be strong in-
hibitors of histaminase. Imidazole and derivatives can be included in 
the same category. Imidazole
1 
itself1 is said to be a strong histaminase 
inhibitor in vitro. Some of its derivatives, however, such as imidazole 
acetic acid, :imidazole lactic acid, histidine and uric acid, are only 
w·eak inhibitors. 
Aliphatic monoamines and particularly guanidines (guanidine, arnino-
gnanidine) are strong inhibitors of histaminase. According to Schul~r 
(1952) aminoguanidine is the strongest inhibitor of histaminase, exhibiting 
maximal inhibition in concentrations of 0.001 mM/1. Guanidine is a 
relatively weak inhibitor according to the same v-mrker (10 mM/1 for 
maxinnrm inhibition). Aminoguanidine may act not only as a guanidine 
but also as a carbonyl reagent due to its reactive imino group. 
3. Ivlechanism of inhibition 
The action of carbonyl reagents as histaminase inhibitors has been 
attributed to binding with the active aldehyde group of pyridoxal which 
was believed to be a co-enzyme of histaminase. As already mentioned, 
the available experimental evidence does not substantiate the sugge stion 
that pyridoxal is a co-enzyme of histaminase. 
It l-Tould appear, however, that the de-amination of histamine by 
histaminase may take place in a manner similar to the de-amination of 
other arrdnes for which pyridoxal is a co-enzyme; i.e. an active aldehyde 
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group may be involved in histaminase which forms a Michaelis' complex 
with the substrate similar to the Schiff's base (pyridoxal-substrate 
complex) formed in the de-amination reaction in which pyridoxal is 
involved. 
Thus, the reactive amino groups of the carbonyl reagents mey- bind 
with the reactive aldehyde groups of histaminase (as in the case of 
pyridoxal), and thus inhibit the formation of the enzyme-substrate 
complex. 
The inhibitory action of diamines, monoamines and guanidines, some 
of which may serve as substrates, may be qualitatively similar to that 
of carbonyl reagents; i.e. due to binding of the active amino groups 
of the compound with the reactive aldehyde groups of the enzyme. 
If the affinity (reaction velocity of substrate-en~ complex 
formation) of the compound is greater than its intrinsic activity* 
(reaction velocity of substrate-enzyme breakdown), then the compound 
will act as competitive inhibitor. When the reverse is true, the 
compound serves as substrate. In fact, this series of compounds 
represents an excellent tool by which the stereo-chemical or physico-
chemical factors which determine affinity and/or intrinsic activity 
may be studied with advantage. Such information is now in great need 
for a fundamental understanding of enzyme-substrate and drug-receptor 
systems. 
* The terms "affinity" and "intrinsic activity" as used here, have 
been adapted from Ariens ~ al. (1954). 
D. Effects of Histaminase Inhibitors_!!!~· 
1. On histamine metabolism: 
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The studies of Schayer and associates (1952, 1953, 1954) in this 
connection have been referred to in the discussion of histamine metabolism. 
This group was able to show that histaminase inhibitors have a specific 
effect on a certain metabolic pathway of histamine metabolism. Thus, 
aminoguanidine representing a potent histaminase inhibitor depressed 
the excretion of urinary histamine metabolite A in all species studied. 
The effect of this compound on the over-all histamine metabolism in 
different species would then be expected to be in proportion to the 
relative importance of this metabolic pathway (giving rise to histamine 
metabolite A) in that species. 
Am.inoguanidine, therefore, would be expected to cause a major 
alteration in histamine metabolism mainly in the rat and to a lesser 
extent in the guinea pig, and essentially no effect in the mouse or 
eat. 
A similar inhibition of metabolite A was noted with isoniazid and 
iproniazid. The doses of isoniazid required to bring about a marked 
effect were over 100 times larger than those of aminoguanidine for the 
same degree of inhibition. Iproniazid was even less potent requiring 
twice as much as isoniazid for the same effect. 
The above results on the relative activities of aminoguanidine, 
isoniazid and iproniazid are in agreement with the activities of these 
eompoun:is as histaminase inhibitors when measured in vitro (Schuler 1952). 
It should be noted, however, that these studies were per formed utilizing 
extremely small doses of histamine of the order of 0.05 to 1 mg./Kg. l.cu~ 
The molar ratios (inhibitor/histamine) of injected doses far marked and 
complete inhibition of metabolite A can be calculated in each case. 
According to such calculations made from the data of Schayer.!!: .!;!.(1953), 
this ratio in the case of aminoguanidine is of the order of 20 to 25; for 
isoniazid about 2000 , to 3000 and for iproniazid nearly 4000 to 6000. 
In general, the inhibitor had to be injected in molar doses many times 
greater than the injected doses of histamine in ord.er to show its character-
istic effect. This may be taken as an indication of the low affinity of 
the inhibitor for the enzyme as compared to histamine under in ~ conditions. 
An inhibitor,y effect of isoniazid and aminoguanidine was also noted 
on the oxidation of injected radioactive cadaverine (Scbayer ~ al. 1954a), 
thus providing additional evidence that their effect was related to inhibition 
of histaminase. 
It is of interest to note that neither aminoguanidine nor isoniazid 
had any effect on the excreted amounts of histamine metabolite B, suggesting 
that their effect is specific for the metabolic pathway giving rise to 
·metabolite A. The decrease in the amount of histamine normally excreted 
-in the fonn of metabolite A was compensated in these animals by a pro-
portional increase in, the amount of histamine excreted in the free form. 
In contrast, iproniazid, in relatively large doses, in addition to 
its e f fect on metabolite A, had an inhibitory action on metabolite B as 
well, particularly in mice and cats where this urinary metabolite pre-
dominates. It is therefore suggested that this compound aiao blocks the 
second metabolic pathway of histamine metabolism which is not affected 
25 
by potent histaminase inhibitors. 
2. On the pharmacological effects or histamine on smooth muscle: 
Arunlakshana, Mongar and Schild (1954) reported recently that certain 
histaminase inhibitors have a specific potentiating effect on histamine 
induced contractions of the isolated guinea pi:g ileum. They attributed 
this potentiation to inhibition of histaminase since no change occurred 
in the response of the tissue to acetylcholine or to histam\ne analogues 
whieh are known not to be attacked by histaminase. A similar potentiation 
was reported for the effects of histamine on isolated preparations of guinea 
pig tracheal chains and uterus. According to the authors, the effect of 
these compounds in potentiating histamine-induced hypotension in cats was 
not regularly reproducible. 
It is interesting to note that the ~ degree of potentiation* 
obtained by these workers was never larger than 2.0. T.lm.s, at optimal 
concentrations or the inhibitors used, the contraction due to a given dose 
of histamine was never greater than that to be expected with twice that 
dose of histamine. In general, the magnitude of potentiation was relatively 
small. 
* The effect of the inhibitor on a histamine response is best measured 
by taking the ratio of: dose of histamine to produce an effect in the 
absence of the inhibitor, to the dose or histamine necessary to produce 
the same effect in the presence of the inhibitor. 
The theoretical basis for such a ratio has been discussed by Clark 
( 1937) and Gaddum ( 195 5) • 
Throughout the present thesis this ratio is designated as degre~ 
potentiation. 
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Another interesting point is that the optimal concentrations of the 
inhibitor were several thousand times larger than the test dose of hista-
mine. Roughly, the minimum molar ratio of inhibitor/histamine*for sane 
of the more potent compounds used were: for aminoguanidine 1,000, for 
semicarbazide 10,000 and .for imidazole l,ooo,ooo. Here again, the results 
may be interpreted as indicating a very low affinity of the inhibitor for 
the enzyme compared to the affinity of histamine under these experimental 
conditions. 
Of some hnportance perhaps is the fact that the same compounds, when 
given in doses larger than an optimal dose, show a reversal of the potenti-
ating effect then acting in an antihistaminic fashion. This type of reversal 
of action is often encountered in systems where two compounds act on the 
same receptor in a competitive manner (Ari ens et a:l. 1954,1955). Thus, 
the results of Arunlakshana et ~· may indicate an influence of the tested 
compounds on smooth muscle histamine receptors rather than on ·histaminase. 
At least this possibility is not excluded by their results. In this con-
nection it should be stated that the absence or potentiation or the effects 
of certain histamine analogues which are ·not attacked by histaminase is 
not a conclusive argument against the view expressed here. Due to their 
relative low activity, these compounds have to be given in doses 1,000 
or more times the dose of histamine. Then the molar ratio of a histamine 
analogue to the inhibitor would be 1,000 times smaller than in the case 
of histamine and, therefore, potentiation may not result in this case 
while it does in the case of histamine. 
* Referred to as "drug ratio" by Gaddum (1955). 
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D. J. Smith (19.53) found that stilbamidine, a lmmm histaminase 
inhibitor (Blaschko E .al. 1951), potentiated the vasoconstrictor effect 
of histamine on isolated swine carotid arteries. The concentration of 
stilbamidine necessary to cause a significant effect was 0.01 mM/1. Doses 
of 1 mM/L were 'necessary to cause a significant increase in the reaction 
time. Considering the test doses of histamine used, these amounts of 
stilbamidine represent molar ratios of concentrations (inhibitor/hista-
mine) between 100 and 2000. 
Lindel and Westling (1954) reported a potentiation of the responses 
of bronchioles and urinary bladder of the guinea pig to histamine following 
injections of stilbamidine. The degree of potentiation was again relatively 
small and of the order of 2.0; but the duration of the response was pro-
longed by a factor of seven. In these studies the molar ratios of stil-
bamidine/histamine doses were of the order of 200 to .5oo. 
The same authors investigated the effect of stilbamidine in vitro 
using guinea pig liver as the source of the enzyme, and measuring hista-
mine inactivation. They found stilbamidine to cause 100% inhibition in 
concentrations of 0.01 mM/1, .50% inhibition in 0.001 mM/1 and just measurable 
effect in 0.00001 mM/1. In these in vitro results the molar ratios of 
inhibitor/histamine were between 200 to 10,000 times smaller than ~ vivo. 
For 100% inhibition the molar ratio in the in vitro case was 1.0 for .5o% 
o.o.5 and for just measurable inhibition o.oo.5. 
In general then, the reported potentiation of histamine effects on 
smooth muscle preparations are of a relatively small magnitude. In most 
cases the smooth muscles used were from a species known to be very sensi-
tive to histamine (i.e. guinea pig). Therefore, it is not clear from 
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the published studies whether the observed small degree of potentiation 
is due to a weak ability of the inhibitor or perhaps it is related to 
the limitations imposed by the alre~ high sensitivity of the tissues 
used. 
It is further interesting to note that, in all instances, the molar 
ratios of inhibitor/histamine, for a significant potentiation of the 
pharmacological effect, were relatively large and of the order of 1000 
or more, even in the ease of the most potent histaminase inhibitors lrnown. 
3. On histamine stimulation of gastric acid secretion: 
Very recently, Ivy et al. (1955a) reported that aminoguanidine 
--
(0.1 mg./100 gms. s.cu.) did not alter the volume output or acidity of 
gastric secretion in rats injected with histamine (1 mg./220.250 gms.). 
Their studies were made using the ''subacute" (pyloric and esophageal 
ligation) and "chronic gastric fistula" methods. They obtained similar 
results in dogs where aminoguanid:ine (10 mg./Kg. s.cu.} failed to increase 
or prolong the gastric secretary response of the Heindenheim pouch to 
histamine (0.1 mg./Kg. of diphosphate). 
The same group, in a later canmunication (1955b), reported that large 
doses of aminoguanidine (50-75 mg./Kg.) did potentiate the gastric secretory 
response of dogs to histamine; greater doses of the compound stimulated 
gastric secretion in the absence of histamine. It is not clear from these 
latter studies whether the apparent potentiating effect of the large doses 
of aminoguanidine was actually due to histaminase inhibition or perhaps to 
an additive effect between the secretor:r stimulus or histamine and that 
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of aminoguanidine. 
The observation that aminoguanidine is a stimulant of gastric 
secretion i s not surprising since this compound possesses all the 
active moieties which Lee and Jones (1949) described as necessary for 
his tamine-like activity. 
III GENERAL EXPERIMENTAL APPROACH TO THE PROBLEX 
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In the following studies, the selection of pharmacological effects 
and species was made on certain ! priori considerations. As a first 
approach, it was reasoned tha.t if histaminase plays a significant role 
in the in vivo inactivation of injected histamine, pre-treatment with a 
--
histaminase inhibitor would be expected to potentiate histamine toxicity. 
It was further felt that such potentiation might be more evident in species 
that are relatively insensitive to histamine toxicity. The effect of the 
inhibitors was therefore first studied on histamine toxicity in rats and 
mice. 
The effect of histaminase inhibitors was next studied on the action 
of histamine on isolated intestinal strips. The well known effect of hista-
:rrj_ne on such preparations is to cause contractions. It was felt that this 
preparation would be suitable for the present problem since it has been 
repeatedly reported that the intestinal mucosa of many species has a high 
histaminase content. In such a preparation, inhibition of histaminase 
would be expected to result in a potentiation of the histamine effect, 
if indeed the en~me plays a limiting role in the action of histamine. 
Here again the choice of species was made on the same grounds as in the 
toxicity studies. Intestinal strips were therefore taken from a species 
which is relatively insensitive to histamine (i.e. rabbits). 
As another approach the influence of histaminase inhibitors on 
histamine induced l'zy'potension was studied in cats. This is a relatively 
sensitive response in a species which is moderately sensitive to the 
toxic action of histamine. It was therefore thought that it might provide 
a good index of possible potentiation of histamtne effects. 
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Finally, histaminase inhibitors were used in mice in attempts to alter 
the toxicity of compound 48/80 lmown to be a histamine liberator. This 
was used as an approach to obtain information on the possible role of hista-
minase in the inactivation of liberated endogenous histamine. 
The compounds used were selected according to their known ability 
to inhibit histaminase in vitro. Most experiments, however, were made 
with a small series of compounds which were selected as the most potent 
representatives of all the chemical types known to possess histaminase 
inhibitory activity ~ vitro. 
The doses of the inhibitors are expressed as millimoles (mM) of the 
active base per unit body weight or (in tests with isolated tissues) per 
milliliter of the solution. This was done to facilitate comparison of 
the activities of the different compounds. 
One millimole dose represents a dose in milligrams equal to the 
molecular weight of the compound under study. In cases where a compound 
with a monovalent active base is in the form of a bivalent salt, one half 
of the molecular weight is taken as equivalent to a millimole of the active 
base. The doses of histamine are expressed in the more conventional form 
of milligrams. 
The compounds used are listed in Table 1 with the milligram equivalents 
of each compound for one millimole of the active base. 
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Table 1. Milligram equivalents per millimole of active base of hista-
minase inhibitors used. 
Compound 
1-Allyl urea 
2-(2-Amino-etbylamino)ethanol 
Aminoguanidine. so4 • H2o 
Atabrin .2HCL 
Bi-guanidino acetic acid 
Chloroguanidine • HCL 
n-Deeylamine 
3, 4 Di-aminotoluene • 2HCL 
Ethyl-phe~l-succinamide 
Gu~l urea • so4 
Hydroxylamine • :OCL 
Imidazole 
Iproniazid (Marsilid) 
Isoniazid (Rimifon) 
Met~l-phe~l-hydantoin 
Phenyl-hydrazine • HCL 
Piperazine ~drate 
Piridoxamine • 2IDL 
Semicarbazide HCL 
Stilbamidine 
Thiamine • HCL 
Thiosemicarbazide 
mg. equivalents 
100 
104 
113 
544 
174 
290 
157 
195 
209 
156 
70 
68 
169 
180 
196 
145 
194 
2L.l 
112 
511 
331 
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IV INFLUENCE OF HISTill~INASE INHIBI~)RS ON HISTAMINE TOXICITY 
A. Experiments in rats: 
1. Introduction 
In the rat, according to the studies of Schayer 
~ !:.!.· (19.52--19.54), the major catabolic pathway of hista-
mine metabolism is via a system which is inhibited by 
the injection of histaminase inhibitors. It appears, 
therefore, that in this species, histamine is catabolized 
mainly through the action of histaminase. The above 
studies dos not give any information on whether the 
action of histaminase ~ ~ is on the biologically 
active histamine or on forms of histamine which have 
undergone a primary biological inactivation (such as bound 
histamine). 
Since the rat is also highly resistant to the 
toxic effects of histamine, it was desirable to test 
whether this insensitivity was in aey way related to the 
activity of histaminase. 
In general, the present series of experiments 
was designed in an attempt to show whether histaminase 
is involved as a first step in the biological inactivation 
of histamine in this species. 
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2.. Methods 
The animals were pretreated with the indicated 
dose of the inhibitor (or with saline for the controls) 
by subcutaneous injection. One hour later, histamine 
diphosphate was injected intraperitoneally. 
The choice of the one hour interval between the 
injections was based on preliminary observations, when 
it was found that the toxic action of large doses of 
certain inhibitors did not appear until one hour (or later) 
after subcutaneous injection. In our own observations, 
this was true of semicarbazide, thiosemiearbazide, 1!!-
dazole, isoniazid, iproniazid, stilbamidine, and, to a 
lesBer extent, for aminoguanidine and atabrin. A 
similarly delayed action for semicarbazide and thio-
semicarbazide has been reported by others (Jenny and Leei 
1953 ). 
It was felt, therefore, that at least some of 
these compounds may not manifest their maximum activity 
in less than one hour. Furthermore, this interval 
allowed sufficient time for absorption and possible 
inactivation of the enzyme. Others, working with some 
of these compounds for the inhibition of monoamine 
oxidase ~ !!!!• found it necessary to wait for approxi-
mately one hour "1for the enzyme to be inhibited", even 
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though the compounds were given intravenously (Griesemer 
et al. 1953). 
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In the present experiments, histamine was administered 
intraperitoneally as it was £elt that the toxic action o£ 
the drug was thus prolonged and, there£ore, allowed s~­
£icient time £or the enzyme to mani£est its possible effects. 
In the majority of the animals which succumbed, 
death occurred between one-half and two hours after intra-
peritoneal injection of histamine. A few did not die for 
as long as six hours after injection. The mortality was 
always recorded over a 24-hour period following histamine; 
however, no deaths were observed past six hours. 
The dose of the inhibitor is expressed as millimole& 
(mM) per 100 grams of body weight. Histamine is eapressed 
as milligrams (mg) of the diphosphate per 100 grams of body 
weight. All doses were administered in 0.5 ml. volume. 
The animals used were from the same source (and, 
presumably, of the same strain), and in weight ranges of 
100 ! 10 gms. or 125 ! 10 gms. Within each weight range, 
the animals received the same dese of inhibitor and hista-
mine, regardless of exact body weight. 
A control group (pretreated with saline), of the same 
weight range as the experimentals, was included each day. 
3. Results 
a. Determination .2£ ~ ~ ~ .2£ histamine. 
The LD5o dose of histamine diphosphate given intra-
peritoneally was determined in groups of saline pretreated 
rats on two occasions. 
The log dose-probit regression lines are shown in 
Figure 1. · In the first determination, each plotted point 
represents mortali~ in groups of 20 animals. In the 
second determination, each point represents mortality in 
groups of 40 animals. 
Table 2. shows the LD,5o with its 95% confidence 
limits for each line. The two determinations of the LD5o 
agree well within experimental error. Similarly, the 
standard deviation of the regression, which is calculated 
from the slope, shows a statistically non-significant 
difference between the two determinations. 
TABLE 2. LD5o AND CO:mt'IDENCE LIMITS OF INTRAPERITONEAL 
. HISTAMINE TOXICITY IN RATS. 
95% confidence 
limits 
Total number 
of animals. LD,5o Upper Lower 
Ist Determination 60 190 207 174 
2nd Determination 80 168 188 1.50 
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b. Subcutaneous toxicitw of aelected histaminase 
inhibitors• 
Bef'ore attempting to determine the effect o:f hista-
minase inhibitors on histamine toxicity, it was desirable to 
ascertain the toxicity of s:ome o:f these compounds. A know.-
ledge of the toxicity of the compound is essential in 
evaluating its posaible contribution to the over-all toxicity 
wfien such compounds are used as potentiators of histamine 
toxicity. 
The results of these studies are given in Table 3. 
Determination of rn50 was made using 2-.3 dose levels; w.ith 
5 to 10 animals per dose, giving mortalities between 20% 
and 80%. 
TABLE 3. SUBCUTANEOUS TOXICITY OF CERTAIN COMPOUEDS IN BATS. 
Compound LD 
with 95% eo~~dence limits 
' •JJiM/100 gms. 
. . . - . . . 
Amino guanidine 1.7 (1.4 - 2.1) 
Hydroxylamine 0.089 ( o.oao 
-
0.097) 
Imidazole 0.92 (0.86 
-
1.00) 
Iproniazid 0.30 (0.20 
-
0.82) 
Isoniazid 
€1.24 (0.21 
-
0.27) 
Phenylhydrazine 0.15 (0.10 - 0.20) 
semicarbazide 0.23 (0.16 
-
0.32) 
Stilbamidine 0.27 (0.2:3 - 0.32) 
c • ;;;E.;.;.f,;;.f.;;;.ec.;..;;.t £! !. fixed ~ of ~ inhibitor on 
the mortality induced .Ez. .!!! !i!?Su. ~ £! 
histamine. 
In this series of experiments, all u.inhibitors"1 were 
injected in a dose of 0.1 ~100 gms. body weight. Hista-
mine diphosphate was given 1n a dose of 180 mg./100 gms:. body 
weight, a dose alightly smaller than the LD5o found in the 
first determination. In all other respects, the procedure 
was identical -as described under Methods. 
• series of ZO compounds were tested with this 
method. These substances were either known to possess hista-
minase inhibitory ac ti vi ty ~ vitro or had s.truc tural formulas 
which suggested possible histami~e inhibitory activit~ 
l.e. they .had basic diamine components as part of their 
structure • 
.AJ.l compounds were tested in groups of 10 animals, and 
they were eG>mpared to a ·similar group of saline controls 
injected the same day. In all, 100 animals were used as con-
trt~ls. A. Chi-square test of homogeneity showed that tbe 
variation in mortality in the controls from day to day was 
within experimental error, suggesting that the grou~of 
animals employed were derived from a homogeneous population 
in regard to their sensitivity to histamine toxicity. 
The results for 17 of these compounds are given 1n 
the upper part of Table 4• The other three compounds tested 
were hydroxylamine, stilbamid-ine, and phenylhydrazine. 
They were toxic at this dose level of 0.1 ~100 gms. When 
tested at 0.01 ~100 gms. dose level, they were found to be 
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inactive in potentiating histamine toxicity. These results 
are given in the lower part of Table 4. 
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TABLE 4 • INFLUENCE OF HISTAMINASE INHIBITORS ON HISTAMINE 
TOXICITY IN THE RAT. 
Groups of 10 animals pretreated s. cu. with 0.1 mM 
/100 gms. body weight of the inhibitor, one hour before 
histamine diphosphate 180 mg./100 gms. i.p. 
Saline Controls Differences from 
% Mortality the controls of 
Compound . 65w.~ the same day. 
I. Allyl-urea 60 'flO 
2.. Amino-ethanol 70 +20 
3. Amino guanidine 20 +10 
4. Bi-guanidino acetic acid 50 +40* 
5. see. Butoxy-diamino triazine 90 +40* 
6. Chloroguanidine 90 +60* 
7. n-Decylamine 90 +40* 
8. Di-aminotoluene 80 +20 
9. Ethyl-phenyl-succinamide 80 +30 
10. Guanyl urea 40 -20 
11. Imidazole 50 +40* 
12. Iproniazid 80 +10 
13. Isoniazid 90 +20 
J.4. Methyl-phenyl-hydantoin 90 -t60* 
15. Piperazine 80 +20 
16. Plridoxamdne 90 +2-0 
17. Semicarbazide 50 -20 
4l 
Table 4. (Continued) 
Same at 0.01 ~100 gm. dose of the inhibitor 
18. Hydroxylamine 
19. Phenylhydrazine 
20. Stilbamidine 
60 
70 
60 
•20 
+10 
+20 
i~ Mortality significantly different from the controls 
( P < o.o.5 >. 
~~ Average of 100 animals in groups of 10 for 10 different 
days. 
d. The effect of various doses of selected 
inhibitors on several lethal and sublethal 
doses ££ histamine. 
To obtain further information on the possible in-
fluence of potent histaminase inhibitors on histamine 
toxicity in rats, a selected group of compounds was tested 
at several dose levels of the inhibitor and of histamine. 
The group consisted of five compounds: .Aminoguani-
~' imidazole, iproniazid, isoniazid, and semicarbazide. 
Aminoguanidine was selected because it has been reputed to 
be the most potent histaminas.e inhibitor in vitro {Schuler, 
1952) and in vivo (Roberts, 1954). ]midazole was included 
because it was found to be a consistent potentiator of 
histamine toxicity in preliminary experiments. Iproniazid 
and isoniazid have been shown to inhibit amine oxidase and 
histaminase respectively. Finally, semicarbazide was in-
cluded since it is the most commonly used histaminase in-
hibitor in vitro. 
-
The experimental design was as already described 
except that two or more groups oi' controls were given 
different doses of histamine each day. The histamine 
doses were such as to cover the main portion of the dose-
mortality regression of histamine. Groups of animals 
treated with histaminase inhibitors were given the same 
doses or histamine so that the effect of the inhibitor was 
tested on the entire dose-mortality line of histamine. 
Thus, the LD5o of histamine, in untreated animals, 
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is compared to the ID.5o o£ histamine 1n animals p.revioualy 
treated with a given dose o£ a compound. The toxicity ratio 
is then calculated as:: 
Histamine LD5o in controls 
Toxicity ratio = Histamine LD5o in treated 
A ratio greater than l.G represents potentiation, while a 
ratio smaller than 1.0 indicates antagonism. The 95% 
eon£idence limits o£ this ratio can be calculated with 
probit analysis. The method o£ statistical analysis used 
was as described by Litch£ield and Wilcoxon (1949). The 
results are tabultated in Table .5. 
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TABLE 5. HISTAMINE TOXICITY (LD,5o) IN CONTROL AND TREA'mD RATS. 
TREATMENT Total Histamine LD50 Toxiei ty ratio 
number mg/100 gms. with 95% con-Ifas :. Dose mM/ of controls f treated fidence limits Compound 100 gms. B.llim.als I 
I 
Aminpgua.nidine l 1.7 o.o1 40 179 192 0.93 (0.78-1.12) 
! I 
n 
' 0.50 60 150 lSO 1.00 (0.8.5-1.21) 
-
n o.85 50 152 130 1.17 (0.95-1.43) 
' ' .. I 
Imidazole 0.92 0.10 150 177 118 1.50*(1.2.5-1.80) 
n : 0.23 40 188 137 I 1.37 (1.14·1.64 J I I I I 
- l I n I 0.46 50 162 45 3.60 (3.00-4.30) 
I 
- I 159 n 0.50 50 10.7 14·9*(11.5-19.4) 
I 
- ' Iproniazid 0.30 0.15 .so 1.58 139 1.14 (0.95-1.37) 
' Isoniazid 0.24 0.12. .so 158 171 ! 0.92. ( o. 77-1.10) 
Semicarbazide I 0.23 0.115 50 173 166 I 1.04 (0.83-1.30) 
* Histamine toxicity regression lines of treated and control groups 
showed significant deviations from parallelism in these tests (see Figure 2). 
i 
I 
Molar Drug 
Ratio 
inhibi.tor/ 
histamine 
o.o2 
1.02 
1.72 
1.17 
0.38 
0.87 
0.92 
0.29 
0.23 
0.21 
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4• Discussion 
The results of the determination of histamine 
toxicity on two occasions show that the response is repro-
ducible. The first determin~tion of LD5o was made at the 
start of the series of experiments with rata, while the 
second determination was made when the aeries was approaching 
completion. This represents an interval of time of approxi-
mately s.ix months. The agreement in the median (LDso> and 
standard deviation of the two lines indicates that, in both 
cases, the samples were from the same population of rats 
in regard to their sensitivity to histamine toxicity. A 
similar conclusion is reached by comparing the per cent 
mortalities of the control group on different days. In 
this case, the Chi-square test indicates no significant 
deviations from homogeneity. The results, therefore, may 
be considered as entirely comparable, and the statistical 
procedures applied for their analysis as valid. 
From the dose-response regression of histamine 
toxicity, it can be inferred that the method used in series 
c. (i.e. comparing the histamine toxicity in single groups 
of treated. animals to that of saline treated controls) is 
sufficiently accurate to distinguish clearly a potentiation 
of a degree of twofold or greater. 
It can be seen in Table 4. that a number of groups 
treated with histaminase inhibitors showed mortalities 
high•r than that of the concurrently injected controls. In 
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certain cases (indicated in the Table), the mortalities 
were signi:ricantly higher than the controls (P < 0.05). 
However, we consider o£ signi£icance the fact that in no 
case was the mortality o£ a treated group signi£icantly 
diffepent £rom the average mortality o£ all the control groupa. 
The dose o£ 0.1 mWlOO gms. for the inhibitors. was 
selected on the basis of data for ~ vitro inhi~ition given 
by Zeller (1951), Zeller et al.(l952) and Schuler (1952). 
It would be expected to give a sufficiently high concentra-
tion in the tissues for complete inhibition, even in the case 
of a relatively large degree of excretion and/or inactivation 
in the body. As- can be seen from Table 3., most of the com-
pounds with strong in vitro activities could not be given in 
much higher doses due to the limitation of their own toxicity. 
In those cases where compounds were given in smaller doses 
(see Table 4 and Table 5 ), they were found to exert no 
demonstrable effect. · 
The consistently higher mortalities in most of the 
treated groups sug~st that the drugs were given in sufficient 
amounts to contribute to the mortality of the treated animals. 
It is not certain whether this can be attributed at all to 
histaminase inhibition. 
The significant fact is that, under these experimental 
conditions, all compounds used (some of which are known to 
poss.ess strong histaminase inhibitory activities .!,!! vitro) did 
not cause any major potentiati~n of histamine toxicity in rats, 
as would have been anticipated if histaminase played an 
important role in the marked insensitivity of this species 
to histamine toxicity. 
An accurate and quantitative measure of the ability 
of a compound· to alter histamine toxicity can be obtained 
from the toxicity ratio and its confidence limits (see 
section d.). 
This ratio is analogous to the "dose ratio" used in 
- -
various pharmacological investigations and to the "potency 
ratio"· employed in bioassays. The theoretical basis of 
such a ratio in relation to drUg action has been discussed 
by A. J. Clark (1937) and Gaddum (19.5.5 ). 
As used here, the toxicity ratio measures: the degree 
of histamine potentiation following pre-treatment with a 
given dose of the compound un~er test. 
It can be seem from Table .5. that, with the excep-
tion of imidazole, in all cases the toxicity ratio is not 
s.ignificantly different from 1.0 even with maximum tolerated 
doses (i.e. half of LD,5o) of the compound. Using larger 
doses of a compound can not be expected to give any reliable 
information since the over-all mortality will be effected 
by the compound's own toxic!~, as well as by histamine. 
In discussing the negative results, the ratio of 
the dose of the inhibitor to the dose of histamine must 
be considered. This ratio may be called the drug ratio 
since, in a general sense, it is similar to the ratio intro-
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duced by Gaddum {1955) under this term. 
The drug ratio may be de~ined as: 
dose (in mM) of compound under test 
Drug ratio • dose (in mM) of histamine 
The drug ratio, for each compound used in the second 
series o~ experiments (section d.), is calculated by using 
each dose of the compound and the LD5o dose of histamine. 
The values are shown in Table 5. It ean be seen that, under 
these conditions, even when the maximum tolerated doses o~ 
the compound were used, the drug ratios ~ere relatively small, 
suggesting that the concentration o~ the -compound in the 
tissues could not have been in any large excess over the 
concentration o~ histamine. 
I~ the above interpretations are correct, then 
perhaps the doses o~ the inhibitor used in the experiments 
of section~· (i.e. 0.1_ ~100 gms.) may not have been 
sufficiently high to compete advantageously with the 
relatively large doses o~ histamine. In those studies, 
the amount of histamine given was about 0.59 ~100 gm. 
(180 mg. o~ the diphosphate). Thus, the molar drug ratio 
of the administered inhibitorlhistamine was 0.17, i.e. in 
favor of histamine. In addition, histamine was given by a 
route (intraperitoneally) which ~avored higher tissue con-
centrations than what may be anticipated from the sub-
cutaneous injection of the inhibitor. Furthermore, a part 
of the inhibitor may bave been destroyed during the one 
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hour period between injections. It would be expected, there-
fore, that under these conditions, the molar ratio (inhibitor/ 
histamine) following injection of histamine, was greatly in 
favor of histamine. Thus, unless the affinity of the in-
hibitor was much greater than that of histamine, little or 
no effect might be expected. 
The negative experimental results, then, may be 
interpreted to mean that the inhibitors tested were not 
sufficiently potent to manifest their effect in the presence 
of large doses of histamine under the experimental conditions 
employed. 
Imidazole was the only compound producing a consistant 
potentiation in repeated tests. However, as can be seen from 
Table 4., the degree of potentiation varied greatly in different 
trials. The reason for this variability is not apparent. 
One must consider the possibility that the effect of 
imidazole on histamine toxicity could be of an additive 
nature rather than true potentiation. If the effect were 
additive, and with the maximum dose of imidazole given 
(i.e. half L050 ), the toxicity ratio would not have been 
significantly greater than 2.0. The results show that 
even smaller doses of imidazole gave toxicity ratios greater 
than 2.0. From these considerations, it would seem that 
the effect of imidazole represents a true potentiation. 
The nature of this potentiation is not clear. As 
shown in ~igure 2, in certain eases, the dose~ortality lines 
- - .. -
~ - ... --- - ~ 
for histamine in control and treated groups deviated sig-
nificantly and greatly from parallelism, while in other 
cases, they were distinctly parallel. In view of these 
results, na statements can be made as to the possible 
nature of the potentiation. 
The question remains as to whether the observed 
potentiation was related to inhibition of histaminase, or 
some other phenomenon. Imidazole is a relatively weak ,!!! 
vitro inhibitor of histaminase compared to several others, 
such as aminoguanidine, semicarbazide, and thiosemicar-
bazide (Z.eller, 1951). However, no strict comparative 
studies appear to have been made. 
It should be noted that the maximum drug ratios 
obtained in these experiments with imidazole were not 
greater, and often were smaller, than in the case of other 
inhibitors. Therefore, unless it is shown that imidazole 
is a stronger in .!.!!2, inhibitor of histaminase, it would 
not seem (in view of the over-all results) that the 
potentiation of histamine toxicity by imidazole is related 
to histaminase inhibition. 
In general, it appears, from the present experi-
mental results, that either histaminase plays no role in 
the immediate inactivation of histamine in the rat, or 
that, even with max~ tolorated doses, the compounds 
used (with the possible excep,tion of imidazole) were not 
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e£fective in inhibiting histaminase 1n ~· 
5. summa.rz ~ Conclusions 
A aeries o£ 20 compounds known to possess hista-
minase inhibitory activity~ vitro were tested on their 
ability to potentiate histamine toxicity in rats. When 
given in doses of 0.1 nil~iOO gms., none of the compounds 
tested caused any major potentiation of histamine toxicity. 
Certain compounds caused a small, but significant, poten-
tiation at this dose level. 
In addition, five compounds were tested at several 
dose levels and with several doses of histamine. The list 
included some o£ the better known a.nd most potent in vitro 
inhibitors of histaminase. Using the toxicity ratio 
(i.e. histamine LD5o in controls/ histamine LDso in treated) 
as a sensitive index of the degree of potentiation, it was 
found tha~with the exception of imidazole, none of the 
other compounds potentiated histamine toxicity in rats, even 
with the maximum tolerated doses of each compound (i.e. 
half the compound' s LD5 0 ) • 
The potentiation produced by imidazole was not 
consistent in different experiments, but in general, the 
degree of potentiation was greater than would be expected 
from an additive effect betw&en the toxicity of imidazole 
and that of histamine. It is, therefore, concluded that 
the effect of imidazole represents a true potentiation. 
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The nature of this potentiation is, however, obscure. and 
may not be related to histaminase inhibition •• 
Consideration of the ~ ratios (i.e. dose o~ 
compound under teat/dose o~ histamine) suggests that the 
tissue coneentrations o~ the compounds used (even with the 
maximum tolerated doses) may not have been su:f'~iciently high 
to compete advantageously with the relatively lliarge doses 
of histamine. 
In conclusion, the results of the present experi-
ments may be interpreted to mean that none of the inhibitors 
tested was sufficiently potent to manifest its effect in the 
presence o:f' large doses of histamine under the experimental 
conditions employed. Alternatively, the results may be 
taken to indicate that histaminase plays no significant 
role in the immediate inactivation o:f' biologically active 
histamine in this species. 
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B. Experiments in mice: 
1. I ntroduction: 
Slinilar to the r a t, the mous e is another species known t o be 
h i ehly resistant to the toxic effects of h i strunine. This is of 
p~rticular importance s i nce it has been suggest ed tha t the major 
metabolic pathway and s ite of h i stami ne catabolism a re different in 
t he mous e t han in the r a t. Furthermore t here have b een claims that 
his tami nase may pl ay a limiti~Pa role in hi struni ne toxicity in mice 
(Kind and Hoods , 1953) • For t.hese reasons it was desirable to test 
>rhether h i staminase inhibitors i-rould a lter histamine toxicity in this 
species. It was thought that such a study would make p ossible a compa-
rison of t he a ctivity of different compounds i n the t wo species. 
Available evidence on the effect of potent histaminase i nhibitors on 
histami ne metabolism i n mice indica tes that such compounds had little 
influence on the rnagni tude of maj or metabolic products of injected 
histamine. This is in contra st t o tl1e effect of such compo1ll1d s on 
histe~ine metabolites of tl1e rat. In the mous e, there is a suggestion 
tha t mono-amine oxidase i~~ibitors may a l ter the a ctivity of the 
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normally maj or metabolic patl:n-ray of histamine catabol i sm (Schayer, 1953b). 
2. Methods: 
Hice of the same strain (Harva rd) >-rere used in all ti1e e:><:periments . 
The procedure of pretreatment and h i st.:'U!l.ine i n j ections was similar to 
t hat used in r a t s . All inhibitors ;.rere i n j ected subcute.neously in the 
indica ted doses, one hour before h i sta.rni ne d i phospha te vr:rlich 1-ras given 
intraperitone lly. The rea sons f or t.he choice of ti1e route of admi nis-
tra tion and the time interval behreen inj ections have been already stated 
( see: Toxicity studies i n r a ts , unr.1er 11m.ethods 11 ). All inj ections were 
made in a volume of 0.2 ml. The mice used were in ti-m weight ranges 
i.e. 18 ± l gm. and 20 ± l gm. In a given day 1 the control a11..d experi-
mental groups "Here from the srune weight range. All the e.nimals wit..h.in 
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a •reight range received the same dose. Doses are expressed in millimoles 
or milli grams per 20 gms . of body weight. In ea ch experiment the hista-
minase in.h.ibitors rrere given in isomolar doses to facilitate comparison 
of the results. The mortality 1-m.s recorded over a 24 hour period 
following histamine injections . :Host deaths how·ever occurred within the 
first hour of this period and there were no deaths past six hours after 
histamine injections. In all cases the per cent mortality figures a re 
ba sed on 20 animals per group. 
3. Results: 
a. Determination of the LD50 of histamine: 
The medi an lethal dose (LD 50) of histamine was determi ned in saline 
pretreated mice of a "l·reight range of 20 ± l gm. The results a re shmm 
in the form of a probit regression line in Figure 3. The LD 5o is 41 mg . 
with 95% confidence limits of 40 and 43 mg./20 gms . This determination 
is based on a total of 140 anbnals, in 7 groups of 20 covering the ra11~e 
from zero to 85% mortality 
b. Toxicity of certain histaminase inhibitors: 
In order to evaluate the possible influence of a compound ' s toxicity 
to the over all toxiciv.r -wnen tested in conjuction 1-rith histamine, mea.sm~e­
ments of the subcutaneous LD50 dose of several compounds were made. The 
results are shown in Table 6. They are ba sed on experiments in rrhich the 
toxicity of a compound was tested in groups of 20 animals at 2-3 dose 
levels giving mortalities between 20 and 80%. The LD50 and its confidence 
limits given in the Table vrere calcula ted follorring the method of Litchfield 
a nd Wilcoxin (1949). 
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Table 6. 
Subcutaneous Toxicity of Certain Comp ounds in Mice. 
Compound LD50 with 95% Confid ence Limits . 
mlv1L20 gms . 
Ami nogua.nidine 0. 26 (0. 23 
-
0 . 29) 
Imi dazole 0.23 (0.19 
-
0.28) 
Ipr onia zid 0 .14 (0.11 
-
0.18) 
I soniazid 0.022 (0.019 - 0 .025) 
Quinacr i ne 0 .012 (0.007 - 0.020) 
Semicarba zi d e 0.027 (0.024- 0.031) 
Stilbamidine 0.023 (0.020 - 0.026) 
Thiamine 0.020 (0 .017 - 0.024) 
c. Effect of fixed doses of the inhibitor on the LD 50 of histamine: 
The effect of histaminase inhibitors -vras first tested with a dose 
of 0.002 mN/ 20 gms . The dose was selected on the basis of available 
date of optimal concentrations for inhibition in vitro, which is given 
as being of the order of 0.01 mH/liter for most compounds. The total 
body water of the mouse is given as nea rly 70% of body weight (Cizek ,, 
1954). By assuming a value of distribution equal to the total body 
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wa ter, the above dos e would be expected to give, in the mouse, a concen-
tra tion of 0.07 ~4/liter, if no inactivation or excretion of the compol~l 
occurred. This dose was thought to be sufficiently high to give maximal 
inhibition even in the presence of considerable excretion a nd inactivation, 
if the in vitro results were a t all representative of in vivo activities. 
Since in most ca ses ~~ere was no detectable effect at this dose level, 
certain compounds were tested at a dose level ten times that previously 
used, i.e. 0.02 mM/20 gm. Certain other compounds were also i nclud ed in 
this series but were found to be toxic at this dose level. Such was fm.md 
to be the ca se f or s tilbamidine, atabrin, isonia zid and thiamine. 
To extend t..h.e r ange of doses in 1.rhich t h e inhibitors lvere tested, 
another study was made in Which the inhibitors were given in very small 
doses (0.0002 mM/20 gms s. cu.),i. e.,l/10 that used in the f irst study. 
In this serie~histamine was injected a t a smaller dose s o that the inhibitor 
might exhibit its full effect. 
The results of the three studies a re summarized in Table 7. 
d. Toxicity ratios in trea ted aniroB.ls: 
Since t..h.e results of the above experiments with this species of 
animals ¥Tere l a rgely negative, quantitative measurements of the influence 
of certain s elected compounds on histamine toxicity were performed. This 
was a ccomplished u s ing a method by which the LD50 of hist.."UD.ine is determined 
6o 
Table 7. Horta.lity in Control and Trea ted Groups of Hice After Histamine. 
(3) 
Pre-treatment Histm. DiPO 4 % Hortality LD~o(l) Dose (2) 
Compound mJ:tiL Ogms . w1L2ogms . mML20 gms. Controls Treat ed Difference 
Ami no guanidine 0 . 26 0.0002 30 10 10 0 
0 .002 40 60 95 +35* 
0.002 40 60 75 +15 
0.02 40 35 15 -20 
0.02 40 60 55 -5 
Hydroxylamine 0 .002 40 60 70 +10 
0 . 02 40 35 40 +5 
Imidazole 0.23 0.002 40 60 75 +15 
0.02 40 35 70 +35* 
0.04 30 20 90 +70>~ 
0.04 40 60 90 +30 
I proniazid 0 .14 0 .0002 30 10 10 0 
0.002 30 10 10 0 
0.02 40 35 1~5 +10 
Isonazid 0 .022 0 .0002 30 10 10 0 
0.002 30 10 20 +10 
Phenylhydra zine 0.02 L1.0 45 25 -20 
Piperazine 0.002 40 60 60 0 
0 .02 40 35 40 +5 
Quina crine 0.012 0.002 40 45 35 -10 
Semicarbazide 0.027 0 .0002 30 10 0 -10 
0.002 40 60 70 +10 
0 .02 40 35 70 +35* 
0.02 40 60 95 +35* 
61 
Table 7. Continued. 
(3) 
Pre-treatment Histm. DiP04 % Mortality LD (1) Dose (2) 
Compound mH/~8gms . mM/ 20grns . mM/ 20 gms . Controls Treated. Dif'ference 
Stilba.TJlidine 0.023 0.0002 30 10 10 0 
0.002 40 45 35 -10 
Thiamine 0.020 0.002 40 45 65 +20 
(1) LD50 of the compound as determined separately (see Table 6). 
(2) Dose of the compound injected in each test. 
(3) Dose of hi stamine di phosphate injected in each test. 
* Mortality significantly different from controls (P< 0.05) 
in groups of trea ted animals and compa red to simultaneous determinations 
of histamine LD5o in saline trea ted controls so as to obtai..11. the toxicity 
ratio, i.e. histamine LD 50 in controls/histamine LD 50 in trea ted. This 
r a tio is e.. quantitative measure of t..h.e influence of a compound on histamine 
toxicity as discussed in connection with similar experiments in r a ts. 
Six compounds Here selected for these st:Lldies. The basis for t..h.eir 
selection has been discussed under t he experiments in r a ts. The six 
compotmds were tested in doses corresponding to 1/2 of tl1e compottnds 1 LD 50 
as determi ned previously (see Table 6). Imidazole ~~s tested also in doses 
corresponding to 1/6 and 1/12 of its subcutaneous LD 50 , since it showed 
cons iderable a ctivity in l arger doses. 
The results of all these studies are given in Table 8. 
4. Discussion: 
The toxicity of histamine in saline treated controls seemed to var,y 
in groups of animals of different weight raP~es. In a subsequent study 
(unpublished) it was found that the LD50 of mice of a 1-reight range of 25 + 
1 gms . Has significantly higher than t..h.at for 18 ± 1 gm. This discrepancy 
d isappears if the results are expressed as mg./mouse irrespective of body 
weight. \'Ihen thus expressed the LD 50 of histamine toxicity is found to be 
40 mg./mouse with 95% confidence limits of 44 and 36 mg./mouse and it is 
tl1e same for all Height ranges from 15 to 30 gms. In the determination 
shoHn in Figure 3 with 20 ± 1 ~n. mice, the results are expressed as mg./20 
gm. body weight. Of the compounds tested in the first s eries of experiments 
only lllidazole (in several doses) and semicarbazide (in l arge doses) gave a 
significant apn reproducible potentiation of his~~ine toxicity. 
In tl1e quantitative measurements of toxicity r a tios in anima.ls treated 
with 1/2 the compound's LD 50 , imidazole and stilbamidine gave toxicity ratios 
significantly greater than 1.0. Semicarba.Gide was inactive a t this dose 
Table 8. Histamine Toxicity (LD50) in Control and Treated Nice. 
Histamine LD50 Toxicity Ratio Molar Treatment Total No. ml1L20gms . with 95% Confidence Drug-Ratio 
Compound LD * Dose of Controls Treated Limits I nhibitor/Histamine mM/~8gms. mML20gms. Animals 
Imidazole 0. 23 0.02 80 37 35 1.1 (0 . 9 - 1.1:.) 0.17 
II 0.04 90 40 21 1.9 (1.5 - 2.5) 0 .31 
II 0.115 40 39 17 2.3 (1.8 - 3.0) 0 . 88 
Animo guanidine 0.26 0.13 40 39 36 1.1 (0.85 - 1.4) 1.00 
Iproniazid 0.14 0.07 40 39 30 1.3 (0. 96 - 1.8) 0.54 
I soniazid 0 .022 0.011 40 39 36 1.1 (0 . 85 - 1.4) 0 .09 
Semicarbazi de 0.027 0.0135 40 44 60 0.73 (0 .52 - 0.99) 0 .11 
Stilbamidine 0 .023 0.0115 40 39 22 1.8 (1.3 - 2.4) 0 .18 
* The compound's LD 50 (See Table 6) • 
e 
level, which suggests t hat the potentia.ting effect observed with larger 
doses of this compound (Table 7) is due in all probability to an additive 
effect of the compound's toxicity to that of histamine. The same lJ'..ay be 
said of stilbamidin~1 Since it is inactive in smaller doses and its toxicity 
r atio a t this dose level is not significantly different tl1an 2.0. 
Imidazole is the only compound of those tested which produced a signi-
ficant potentiation in sufficiently small doses to suggest that its effect 
was not of an additive nature. Although the degree was rela tively small, 
e. consist-ent potentiation was observed over the entire r ange of doses tested. 
In contrast to some of ti1e results in r ats, the hi stamine toxicity 
regression lines of control and imidazole treated groups of mice, do not 
deviat e s i gnificantly from par allelism (see Figure 4). Thus, in tl1e cnse 
of mice, the results are not consistent Hith the view t hat imidazole a cts 
as a competitive inhibitor. 
It is in~eresting to note tila t ip~oniazid was without any effect in 
all dose levels tested. According to Schayer (1953b), this compound 
inhibits the major metabolic pathHay of histamine inactivation in tile 
mouse. 
In general, tile results on the effect of histaminase iru1ibitors on 
hist:uni.lle toxicity in mice are similar to those obtained in r a ts. No major 
potentiation occurs with sublethal doses of the inhibitor. Here again, 
even witll maximum tolera ted doses, the molar drug-ra tios (illi1ibitor/hista-
mine) (Table 8) are mostly in favor of histaJ.nine. The i nability of these 
compounds to alter ~~e toxicity of histaL~ine in this species may be 
interpreted as indicating that they are not sufficiently potent to compete 
1-rith l ar ge doses of histamine. At tile same time, the results suggest tilat 
histaminase does not play an important role in the i nsensitivity of mice 
to hi st&u.ine. 
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5. SUIIllllarv: 
lifo :ma.j or potentiation of histamine toxicity occurs in mice following 
trea tment with various potent histarllinase inhibitors. Of ~he compounds 
tested only imidazole caused a significant and cons istant potentia tion 
with subletha l doses. Iproniazid wa s 1-rithout aey effect in the doses 
tested. In all probabilit-y, the apparent potentiation after l arge doses of 
semicarbazide and stilbamidine was due to an added toxici -b.r of the compou...."ld 
and can not be considered as true potentiation. 
In all respects, the results in mice vere simila r to those obtained in 
r ats and may be interpreted in a similar Ill.c'l.nner. 
C. ..Exoer:iments jn guinea ;oigs: 
1. Introduction: 
A few experiments Here performed to determine the influence of certa in 
histaminase inhibitors in guinea pigs. This species differs from r a t s and 
mice by being ver-.f sensitive to histamine. Thus l a r ge mola r ratios of 
inhibitor/histamine may be easily a ccomplished in this ca se. Furthermore, 
histamine catabolism in these animals is reported a s occurring through hro 
main patlnmys, one similar to the major pathway in rats and another similar 
to that in mice (Schayer 1953). 
2. Nethods: 
The experimental design was similar to tha t employed throughout these 
series of toxicity studies. The animals 1-Jere pretreated subcutaneously -vrith 
a dose of the inhibitor 01~ hour before an intraperitoneal inj ection of 
histamine. 
3. Results: 
The LD 50 of histamine diphosphate intra peritoneally 1-1as first determined 
in 5 groups of 10 animals each. The results a re plotted in Figure 5. The 
LD is found to be S.O mg./Kg. with 95% confidence limits of 9.6 and 6.7 
50 
mg ./Kg. 
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T:.11.e effect of certain histamina.se inhibitors on the toxicity of 
7.0 mg./Kg. i. p. of histamine •ras then determined in inhibitor doses 
varying from 0.4 to 0.1 mN/Kg. These were estimated (on previous experi-
ence ·l'l"ith the toxicity of these compounds in mice and rats) to be belovr 
the range of toxic closes for each compound. Thus compounds of relatively 
loYT toxicity were given in higher doses. Table 9 gives a summary of t.lJ.e 
results. The mortality of the controls is based on a total of 30 animals 
and represents the average mortalit,y on three different days. TI1e varia-
tion in the mortality between days was exceedingly marked, but not beyond 
the very large error involved in such a small sample. 
Utilizing the standard dose-mortality regression line (Figure 5) and 
the difference in mortalities of controls and treated animals, an approxi-
mation of the degree of potentiation may be obtained by calculating the 
toxicity ratio of control/treated groups. These values are shown in 
Table 10 along with the molar drug ratios 
4. Discussion and Conclusions: 
(inhibitor/histamine). 
The present studies are not sufficiently extensive to perra.i t any 
general conclusions on the influence of histaminase inhibitors on hista-
mine toxicit,y in guinea pigs. The available results suggest tha t imidazole 
and s~~icarbazide when given in molar doses several times the molar dose 
of histamine are effective in potentia ting histamine toxicity. The effect 
of aminogu.c'lnidine is similar to that observed by Arunlakshana, Nongar, 
and Schild (1954) in the isolated guinea pig ileum. Larger doses appear 
to have an in.lJ.ibi tory effect particularly vrhen compa red to the effect of 
smaller doses. 
5 • Surama;ry: 
A limited study of tl1e effect of four compounds on histamine toxicity 
in guinea pigs gave suggestive evidence tha t imidazole and semicarbazide, 
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in molar doses several times the molar dose of histamine, were effective 
potentia tors . Aminogua11..idine seemed to potentia te i n smaller doses and 
to ~~ibit in larger doses. 
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Ta ble 9. Influence of histaminase inhibitors on histamine toxicity in 
guinea p i gs. 
Trea t1nent 
Dose of 
Inhibitor 
mH/Kg. 
~~1ortali t'<J ** Difference from Controls 
Controls 
Amino guanidine 
f...minoguanidine 
Hydroxylamine 
Imidazole 
Semicarbazide 
O.l 
0.2 
0.2 
43 
60 
60 
30 
70 
50 
+30 
-30 
+20 
* Mortali t-.r significantly different from the controls (P .(_ 0 .05) • 
** Difference in % mortality of treated minus control animals of the same 
day. 
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Table 10. Degree of potentiation of histamine toxicitJ by histaJninase 
inhibitors in guinea pigs. 
Treatment Dose Molar Ratio Potency Ratio* 
Inhibitor/Histamine Treated/Controls 
Amino guanidine 4-4 1.5 
f>..IO.inoguanidine 8.8 0.4 
Hydroxylamine 17.5 1.4 
Imidazole 17.5 2.3 
Semicarbazide 8.8 1.6 
* Calculated from the data of Table 9 and the standard dose-mortality 
regression of Figure 5. 
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A· Introduction 
All published studies on the effect of histaminase inhibitors 
on hista.mine responses of isolated smooth muscle, utilized the 
tissues of the guinea pig. In all cases, the potentiation ob-
tained was of relatively small magnitude, never exceeding a 
factor of 2.0 (Arunlakshana ~ al. 1954; Lindel & Westling, 1954; 
D.J. Smith, 1953) . 
It is possible that this small degree of potentiation might 
be related to the high sensitivity of the tissues of this species 
which may thus act as a limiting factor . 
It was thought, therefore, that potentiation may become more 
evident in tissues which are relatively less sensitive to hista-
mine. This would be particularly true if the low sensitivity 
of such tis sues is related to a high histaminase activity. For 
these reasons tests were made on intestinal strips of other 
species in ·search of potentiation of histamine responses by 
several potent histamine inhibitors. 
B. Methods 
A conventional smooth muscle bath arrangement was used. The 
tissue was suspended in Tyrode's solution and maintained at a 
temperature of' 376 +0 . 05°c . by a surrounding constant temperature 
bath. The recording system consie.ted of a light lever:, writing 
directly on a moving kymograph of an electrical recording system. 
Tissues were suspended in a bath volume of 10 ml& A small 
stream of oxygen was continuously passing throu~h the bath. Hista-
mine or i~hibitors were added to the bath. All doses are expressed 
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as final concentrations taking into consideration the bath volume. 
Tests were made as follows: After the preparation had equilibrated 
to the bath conditions, the submaximal responses to J-4 doses of histamine 
were determined in repeated tests (JJ~ tests per dose). Using the average 
responses, a log. does-response line was obtained to serve as control. 
Subsequently, a g iven concentration of the inhibitor was added to the 
perfusion fluid so tha.t it was in continuous contact with the tissue 
for the remaining period of the experiment. Thirty minutes were allowed 
to elapse before any further tests were made. Following this period, 
the log. dose-response regression line of histamine was again determined.* 
The regression line of histamine after treatment was compared to that 
obtained before treatment. Thus, the potency ratio was calcula ted 
graphically or by using the simplified method described by Burn et al. 
(1950). Potency ratio is defined here as the ratio of a dose of histamine 
required to produce a given submaximal response in the presence of the 
inhibitor to the dose of histamine necessary to produce the same effect in 
the absence of the inhibitor. A ratio greater than 1.0 indicates 
potentiation; less than 1.0 indicates antagonism. This ratio is equivalent 
to the dose-ratio discussed by Gaddum (1955), and to the toxicity ratio 
employed as a measure of potentiation in the toxicity studies of the 
present work. 
*In several preliminary experiments, tests made immediately 
after or as long as one hour after exposure of the tissue to the 
histaminase i~hibitor gave results similar to those obtained 1/2 hour 
after exposure 
H S. I 0 IS c 1<! p 
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Unless otherwise indicated, each concentration was tested in 
three smooth muscle preparations. 
c. Results 
1. Guinea Pig Ileum 
In preliminary experiments, an attempt was made to 
repeat the results or Mongar and Schild (1951) on the potentiation 
of histamine responses by semioarbazide in this tissue. In 
addition, stilbamidine was tested on the same tissue, since it 
has been reported to be effective as a histamine potentiator 
{histaminase inhibitor ?) in certain other isolated tissues 
(D.J. Smith, 1953; Lindel & Westling, 1954). The results of 
these studies are showil.l in Table 11. 
Table 11 
Histamine Responses of the Guinea Pig Ileum 
Before and After Treatment with Histaminase Inhibitors 
Final Cone. Potency Ratio Drug Ratio Compound 
_: -mM/oo Average ± SE Inhibitor/Histamine 
Semioarbazide lo-6 1.9 ±0.1 10-100 
n 
_., 
10 '- 0.5 ±0.2 100,000-1,000,000 
Stilbamidine 10-6 1.09:!:0·3 10-100 
" 
lo-5 1.07!0.2 100-1000 
2. Rabbit Small Intestine 
A determination of the sensitivity of this prepar-
ation to graded doses of histamine was first made. In most 
experiments, histamine gave measurable responses in doses of 
0.25 x 10-3 mM/cc. (0.76 mg/cc. of the diphosphate) and graded 
responses in the range of 0.25 x 10-3 to 10 x lo-3 mM/cc. in 
final concentration. There were no significant differences in 
the responses of different intestinal strips of the same animal 
and the results among different animals were very consistent. 
Figure 6 shows a dose response regression obtained by com-
bining the results of 5 determinations in each dose level from 
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two intestinal strips of the same animal. The precision index 
(~~ of this regression line is 0.17 which indicates that the test 
object is sufficiently sensitive to even small changes of the 
dose. Similar results were obtained in other determinations with 
values of less than 0.2. 
The effect of certain potent histaminase inhibitors on 
histamine induced contractions was tested on this type of prepar-
ation using several doses of each inhibitor. The results are 
summarized in Table 12. 
An interesting finding is that aminoguanidine,in doses of 
0.1 ~~/cc . or larger,causes contraction of the isolated intesti-
nal muscle in a fashion resembling that of histamine. Records 
of this effect are shown in Figure 7. 
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Fig. 7. Spasmogenic effects of Aminoguanidine and 
Histamine on the isolated Rabbit ileum. 
Amino guanidine 
0.4 IDM/cc 
Hi stamina 
I 0.005mMt cc 
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Table 12 
Histamine Responses of the Isolated Rabbit Intestine 
Before and After Treatment with Histaminase Inhibitors 
compound Final Cone. Potency Ratio Drug Ratio ~ ~lllM/ cc Average t SE Inhibitor/Histamine 
Amino guanidine 10 ""6 1.1 ! 0.1 1-10 
" 
10~5 0.6 t 0.2* 10-100 
" 
lo-4 0.5 ± o.r~ 100-1,000 
" 
10.-3 0.3 t 0.1* 1,000-10,000 
Imidazole Io-3 1.0 ± 0.1 1,000-10,000 
" 
1o-l 1.0 ~ 0.1 100,000-1,000,000 
" 1·~0 0.9 f 0.1 1-10 million 
I proniazid 1o-8 1.0 t 0.1 0.01-0.1 
" lo-7 0.7 ± 0.2 0.1-1.0 
" 
1o-6 o.6 f G'.3 1.0-10 
-
" 
lo-5 0.3 ... 0.2 10-100 
" 
Io-4 0.3 + 0.2 100-1,000 
Semi carbazide 10-6 1.5 • 0.1 1.0-10 
" 
lo-5 1.6 ~ 0.1 10-100 
-
" 
lo-4 1.0 + 0.2 100-1,000 
" 
lo-3 1.1 + 0.2 1,000-10,000 
Stilbamidine lo- 2 2.1 + 0.3 10,000-100,000 
" 
1r.o 0.3 + 0.1 1-10 million 
* 
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In these tests, the histamine regression lines before and after 
treatment deviated signi ficantly from parallelism. 
D. Discussion 
The results with semicarbazide in the guinea pig ileum con-
firm the observations of Mongar and Schild (1951). The dose of 
semicarbazide used was that suggested by these authors as optimal 
for potentiation. It should be indicated that the potentiation 
was often of such a small magnitude that its presence could not 
be established before a complete statistical analysis was made 
of the degree of potentiation relative to the experimental error. 
Although no systematic studies were made, it seemed that the 
experimental error of response in the present tests was larger 
than that often reported by the above group (Schild, 1942). This 
may be attributed to the crudeness of theequipment employed in 
these tests as compared to the automatic apparatus used by the 
above authors an~perhaps,to the lack of much experience with 
the method. 
stilbamidine did not possess any potentiating activity in 
the concentrations tested, immediately following and up to one 
hour after the addition of the compound. 
In general, it is important to note that in this test 
preparation very large inhibitor/histamine ratios can be achieved 
due to the extreme sensitivity of the preparation to histamine. 
considerations regarding the quantitative characteristics of 
histamine responses in the isolated rabbit intestine suggest 
that this preparation may serve as a sufficiently sensitive and 
precise biological test object for histamine. It is true that 
the sensitivity, as well as the precision of this preparation, is 
distinctly inferior to that of the guinea pig ileum. The latter 
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responds to concentrations of histamine of the order of l0-5mM/cc. 
and when used in an automatic assay apparatus has been found to 
have a precision index (A ) of about 0.04 (Schild, 1942). Yet, 
the above characteristics of the response of the guinea pig ileum 
to histBmine represent the exception rather than the rule in 
biological systems. The case of the rabbit intestine in this 
connection is more representative of the majority of fairly 
sensitive and precise biological responses {Bliss and Cattell, 
1943). 
The above considerations indicate that if the compounds tested 
had any effect of a reasonable magnitude in the doses used, the 
test object would have been sufficiently sensitive to detect it. 
However, as shown in Table 12, with the exception of stil-
bamidine, none of the compounds tested produced any measurable 
potentiation of histamine responses. The effect of stilbamidine 
is similar to that observed with other inhibitors in the guinea 
pig ileum, in that it is of a small magnitude and it is reversed 
to inhibition in larger concentrations of the compound. In fact, 
most of the compounds tested have an inhibitory action in larger 
concentrations. This is in all probability a non-specific 
depressant effect rather than a true antihistaminic action. 
The list of compounds which were found inactive as histamine 
potentiators on the rabbit intestine included some of the most 
potent inhibitors of histaminase. It is not clear, therefore, 
whether the small degree of potentiation observed after stil-
bamidine was related to histaminase inhibition. Further tests 
must be made to clarify this point. 
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For the present it may be tentatively concluded, from the 
over-all results of tests on rabbit intestine, that histaminase 
does not play any major role i n the immediate biological inacti-
vation of histamine or that none of the compounds tested was 
sufficiently potent to produce a significant inhibition in the 
pr~sence of moderately large concentrations of histamine. 
To distinguish between the two possibilities, there is a 
need of information on the degree of inhibition of histaminolytic 
activity of the rabbit intestine in the presence of concentrations 
of inhibitors and histamine similar to those used in the present 
studies. such measurements must be obtained before a clearer 
interpretation of the results can be made. 
The present findings seem to suggest that the relatively low 
sensitivity of the rabbit intestine to histamine (as compared to 
the guinea pig ileum) is not related to a limitatmon imposed by 
high concentrations of histaminase. 
E. Summary 
rn preliminary experiments, the potentiating effect of semi-
carbazide on histamine responses of the isolated guinea pig ileum 
was confirmed. Stilbamidine had no effect in similar tests. 
The characteristics of histamine responses were studied in 
isolated intestinal strips of the .rabbit. In this tissue, the 
dose-response regression of histamine was found sufficiently 
sensitive to detect even small changes of the dose, having a pre-
cision index (A) of less than 0.2. Aminoguanidine, iproniazid, 
i midazole, and semicarbazide in doses of lo-6 to l o-3 mM/cc. had 
no potentiating effect on the histamine responses of this prepar-
ation. 
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s tilbamidine produced a small but signiricant potentiation 
which could be related to histaminase inhibition. 
From the over-all results with rabbit intestine, it is con-
cluded that, in all probability, the relatively low sensitivity 
of this tissue to histamine is not related to a limiting r ole of 
histaminase . 
I HYPO I R ,spo· SES OF T , CAT TO HIS A I 
A. Introduction 
The effect of certain histaminase inhibitors on the hypo-
tensive responses of the cat to hista_mine was studied by 
Arunlakshana et al. (l954)· They reported that potentiation was 
observed in certain cats and not in others. They give no reasons 
for this inconsistency. There is some evidence that the metabolic 
pathway which is inhibited by histaminase inhibitors plays little, 
if any, role in histamine catabolism in the cat. Other compounds 
hm.;ever, such as iproniazid, were shO\-In to have a profound in-
hibitory influence on the major pathway of histamine catabolism 
in this species (Schayer, 1953). The effect of iproniazid was 
not tested by Arunlakshana et al. 
In the present studies, tests were made on the effect of 
various doses of aminoguani dine, iproniazid, semicarbazide, and 
hydroxylamine on the degree and duration of the hypotensive re-
sponses to small doses of histamine. 
B. Methods 
cats were anesthetized with chloralose (60 mg./kg. i.v.) 
following induction with ether anesthesia. Chloralose anesthesia 
in animals lasted over 10 hours and the blood pressure was 
maintained at relatively high basal levels. For these reasons, 
chloralose was preferable to pentobarbital. 
-The arterial blood pressure was recorded from the cannulated 
carotid on a moving kymograph through a mercury manometer and an 
electrically recording system. 
The femoral vein wa.s cannulated for injections. All in-
jections were made here and were "washed" into the animal with 
3 cc. or saline inrused over a period or 5 seconds. As far as 
possible, the technique or injections was kept constant. 
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In each animal, a dose-response regression or histamine 
hypotension was established by using the average or 3-4 tests in 
each or 2-3 doses giving submaximal responses. A fixed dose or 
the compound was then injected and its effect in blood pressure 
recorded. Histamine injections were then repeated at 3 minute 
intervals over a period or one hour or longer. Thus, dose-response 
regression lines for histamine could be obtained at various time 
intervals after treatment. The histamine dose ratio (i.e., degree 
of potentiation in depression of histamine responses) was calcu-
lated from the dose-response regression lines, before and after 
injection, as described under the experiments with rabbit in-
testine. 
Each compound was tested in 4-6 cats. Usually only one dose 
or the compound was injected in each experimental animal. Oc-
casionally, if no effect was observed on histamine responses up 
to one hour after injection of a very small dose of the compound, 
a larger dose (10 times the previous) was injected and the 
histamine tests were repeated. 
c. Results 
1. Choice of Measure of Response 
A hypotensive (or hypertensive) response in a blood 
pressure record may be measured in a variety of ways. Thus, the 
drop in blood pressure may be expressed as mm.Hg actual drop, or 
as per cent drop (taking into consideration the basal blood 
pressure), or as mm.Hg difference from the base line at the peak 
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of hypotension. various authors have used one or the other method 
on a priori assumptions. No experimental studies, however, were 
ever made to sho-vr which of the above mentioned measures of re-
sponse is preferable. In general, the choice of a measure of 
response must be guided by the characteristics of such a measure 
as shown by the internal evidence supplied by the data. Basically, 
the best measure of response is that which shows a high inherent 
precision. In biological responses, the degree of precision may 
be measured and compared using the precision index, lambda. ( ?t ) , 
introduced by Gaddum (1939). This is the ratio of the standard 
error of the response at all dose levels to the slope of the dose-
response regression line. The smaller values of A indicate either 
smaller error and/or larger slope, i.e., higher precision. 
Several determinations were made of the ~ values for the 
above mentioned measur€s of hypotensive response in a number of 
cases. The example analysed in Table 13 represents the general 
findings. 
Table 13 
Histamine Induced Hypotension in Cats 
Analysis of various Measures of Response 
Histamine dose mcg./Kg. 0.2 0.4 o.8 Slope 
Measure of response Mean responses 
Per cent change 19.5 23.3 25.7 10.4 
Difference from base 
line mm. Hg 12.5 8.0 6.0 -11.2 
Degree of hypotension mm.Hg 
27.5 36.6 Uncorrected 33.0 15.0 
Corrected for conva.riance 26.5 33.0 38.3 19.4 
SE~" 
4-5 0.43 
4.8 0.43 
6.5 0.43 
5.2 0.27 
*Standard error of the response at all dose levels, i.e., square 
root of the variance of error. 
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It seems then that there is no difference in the precision 
of the examined measures of response and the choice becomes 
immaterial. Yet it was desirable to know whether the hypotensive 
response 1 measured in mm.Hg of actual drop*, is in any way re-
lated to the basal blood pressure level, in which case, correcting 
for such a relationship might increase the degree of precision. 
This was tested with convariance analysis shown in Table 14. 
Convariance analysis indicates that the degree of hypotension is 
directly related to the basal blood pressure level. The de-
pendence is statistically significant. At mean basal pressure 
levels of about 130-145 mm.Hg, the dependence is such that a 
change of about 4 mm.Hg in the basal pressure results in a change 
of 1 ~Hg in the degree of hypotension. 
In the case under study, correcting for convariance reduces 
the variance of error to about 53% of its original value and in-
creases the slope to a small extent. Thus the precision index 
for the degree of hypotension is now 0.27. From this it may be 
concluded that the degree of hypotension (actual B.p. drop in 
mm.Hg), when corrected for the variation on the basal blood 
pressure levels by convariance analysis, is a more precise measure 
of hypotensive responses than any of the other commonly employed 
measures. 
~} To be called henceforth degree of hypotension. 
Table 14 
Analysis of variance and U3nvariance of the Degree of 
Hypotension Following Graded Doses of Histamine 
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Corrected for ~ oavariance 
Sums-of-S~ares Sums-of- Sums-of-BBP{*' H~·{l- Products Squares variance 
Total 203 220 504 
Doses 12 41 150 
Error 191 179 354 187 26. 7i-~:t-
Adjusting 
Coefficients 0.879 +1 -1.874 
~ covariance coefficient b = 0.937 
* Basal blood pressure - covariant. 
Degree of hypotension (mm Hg actual drop in B.P.) -variant. 
Standard error of response = 5.17. 
In general, the dose-response regression of histamine hypo-
tension in cats is sufficiently precise to detect even small 
changes in dose. This, in turn, indicates that it may be used for 
testing possible potentiation of histamine effects by histaminase 
inhibitors, since it will be expected to detect even small degrees 
of' potentiation. 
Several dose-response regression lines for different cats 
are shown in Figure 8. They are based on uncorrected means of 
the degree of hypotension at various dose levels of histamine. 
2. Blood Pressure Effects of the Compounds 
Aminoguanidine, in doses of 0.01 to 0.1 mH/Kg. (1.13 
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to 11.3 mg/Kg.) produced a marked hypotensive response (drop or 
50% or more) immediately rollowing intravenous injection. This 
effect had a total duration of 2-3 minutes following which the 
blood pressure returned to essentially control levels. 
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Hydroxylamine was found to have a direct efrect on the blood 
pressure of the cat. When given in doses of 0.02 to 0.08 mM/Kg. 
i.v. (i.e., 1.4 to 5.6 rog./Kg.), it caused a drop of blood 
pressure to 65-50% its original value. The duration of the hypo-
tension depended on the dose and for this range of doses it 
lasted from 2.5 to 4 minutes. A graded response in the duration 
of hypotension was particuls.rly evident in smaller doses ranging 
from 0.002 to 0.0002 mM/Kg. In this range, the degree of hypo-
tension was also a function or dose to a certain extent. The 
minimum dose having any effect on blood pres sure was found to be 
about 0.0002 mM/Kg. (0.015 mg./Kg.); it caused a blood pressure 
drop of about 13% and 10 seconds duration. 
Iproniazid: Smaller doses of this compound (0.01 mM/Kg.) 
had no effect on the basal blood pressure. Larger doses 
(0.1 mH/Kg.) caused an immediate hypotension of small magnitude 
(20-30%) with the blood pressure remaining in lower levels for 
the ensuing experimental period (2-3 hours). 
Semicarbazide had no detectable blood pressure effects in 
doses up to 0.05 mM/Kg. In larger doses (0.1 mN/Kg. ), there 
was an immediate hypotensive response of a small degree (10-25%) 
and a rela.tively short duration (1-2 minutes). 
3. Alteration or Histe.mine Responses After Treatment 
Hypotensive responses to histamine were measured 
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berore and after treatment with each of the above mentioned com-
pounds. The results are given in terms of histamine dose ratios 
in Table 15. A ratio significantly greater than 1.0 indicates 
potentiation, while a ratio smaller than 1.0 indicates antagonism. 
Using the degree of hypotension (blood pressure drop in mm. 
Hg)as a measure of response to histamine, several compounds, in 
various doses, gave results indicating an apparent potentiation 
or antagonism. It was noted, however, that in many cases such 
effects were associated with distinct changes in the basal blood 
pressure levels as compared to control levels existing before 
treatment. 
While, in all cases, their effects were of a relatively 
small magnitude, it was of interest to inquire whether they are 
dependent upon change s in the basal blood pressure level. The 
statistical tool of .:.covariance analysis can be used for this 
purpose. As previously shown, the degree of hypotension is di-
rectly r elated to the basal blood pressure. 
Some of the results were, therefore, corrected for c·Olvari-
ance, utilizing the internal evidence of the data on the depend-
ence of the degree of hypotension to the basal blood pressure. 
The results of this analysis are included in Table 15. 
It is clear that the apparent potentiating effects can be 
attributed entirely to an increase in the blood pressure level. 
This , however, is not true for the observed depressive effects. 
A significant, although smaller, effect persists even after 
correcting for changes in the blood pressure level. 
A study of the records revealed no changes in the duration 
of response before and after treatment with any or the compounds. 
9.1 
However, no extensive measures were made since, in this range of 
doses (giving submaximal hypotensive responses), the duration of 
the hypotensive response to histamine does not appear to be a 
function of dose and varies in the range of 20-30 seconds. 
Table 15 
Hypotensive Responses of Histamine in cats 
Before and After Treatment 
Minutes No. 
Compound Dose After of 
mM/Kg Injection Tests 
Aminoguanidine 0.01 5 
30 
60 
2 
2 
2 
" 
" 
0.05 
" 
" 
0.1 
" 
" 
Hydroxylamine 
II 
" 
0.10 
" 
" 
Iproniazid 0.01 
" 
5 
30 
60 
5 
30 
60 
5 
30 
60 
5 
30 
60 
10 
30 
3 
3 
3 
3 
3 
3 
3 
3 
3 
2 
2 
2 
2 
2 
Histamine Dose Potency Ratio 
Ratio* Corrected for 
Ave t SE Covariance 
1.1 t 0.1 
1.1 t 0.1 
1.1 ~ 0.2 
o.B t 0.3 
1.4 ± 0.2 
0.9 !: 0.4 
0.7 t 0.2 
0.6 :!: 0.2 
o.6 • 0.3 
1.0 :f: 0.1 
1.0 ± 0.1 
0.9 ± 0.2 
1.1 t 0.2 
1.1 :1: 0.3 
1.1 t 0.2 
1.1 t 0.3 
1.0 -* 0.1 
1.1 
0.9 
0.7 
0.6 
0.5 
92. 
Table 15 (Continued) 
Minutes No. Histamine Dose Potency Ratio 
Compound Dose After of Ratio~!- Corrected for 
mM/Kg Injection Tests Ave :1: SE Covariance 
Iproniazid 0.01 60 2 0.9 f 0.1 
0.1 10 3 0.7 i 0.1 0.9 
" 30 3 0.6 t 0.2 0.8 
" 
60 3 0.5 t 0.1 0.6 
semi carbazide 0.05 5 3 1.0 t 0.3 
n 30 3 1.2 :t 0.4 
" 60 3 1.0 t 0.3 
0.1 5 2 0.8 ± 0.3 
n 30 2 0.9 t 0.2 
" 60 2 0.9 :! 0.2 
0.5 5 3 o.6 t 0.3 
30 3 1.2 :! 0.3 
60 3 1.3 t 0.4 
* Ratio of histamine dose necessary to produce a certain degree 
of submaximal hypotension after injection of the histaminase 
inhibitor to the histamine dose necessary to produce the same 
degree of hypotension before injection of the inhibitor. 
D· Discussion 
The doses of the inhibitor and histamine used in the present 
studies correspond to inhibitor/histamine molar ratios of 3,000 
to 30,000 in most cases. Therefore, the inhibitor was in 
sufficiently high concentrations to exhibit its effect even if 
its affinity for the enzyme was much smaller than that of hista-
mine. Nevertheless, no potentiating effects were noted with any 
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or the compounds in the doses used. 
The inability or iproniazid to cause potentiation or hista-
mine hypotension in the cat is of particular importance since 
this compound has been shown to inhibit the major catabolic 
pathways or histamine in this species, in the range of doses used 
in the present experiments (Schayer, 1953). 
The lack .or effect may be related to the brevity of the 
response under study. The present studies should, thererore, be 
extended by investigating the effect or the above compounds and 
particularly or iproniazid on the duration of the hypotensive 
response following large doses of histamine. From preliminary 
observations it appeared that with doses or histamine larger than 
those causing maximum degree of hypotension, the duration of the 
hypotensive response becomes a function of the dose. It seems 
that this response may be used to obtain dose-response relation-
ships for histamine, on which the effect of inhibitors may be 
studied. 
The present results suggest that histaminase plays no role 
in the immediate biological inactivation or histamine in this 
species, and thus it is not a limiting ractor for the response 
under study. 
E. Summary 
The hypotensive response of the cat to histamine was studied 
in its relation to dose and basal blood pressure level. Dose 
response regressions were obtained for the degree of hypotension, 
corrected for basal blood pressure by covariance analysis, and 
found to have an index of precision (lambda) of 0.27. Several 
other measures or response were analyzed but were round to be 
of inferior precision. 
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Aminoguanidine, hydroxylamine, iproniazid and semicarbazide 
were studied for their effects on the degree of hypotension in-
duced by small doses of histamine . Most tests were performed with 
doses of 0.01 to 0.1 mM/Kg. of the compound, corresponding to 
inhibitor/histamine molar ratios of 3,000 to 30,000. No potenti-
ating effects were noted with any of the above compounds in the 
doses used. Aminoguanidine and iproniazid in the larger doses 
had an apparent "antihistaminic" effect. The lack of any 
potentiating effects may be attributed to the brevity of the 
response under study and may be taken to suggest that histaminase 
plays no limiting role in this case. 
VII 
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rt was desirable to test whether potent histaminase inhibit-
ors had any major effect in a variety of other histamine re-
sponses. 
This was tested in a series of experiments of a preliminary 
nature. The results of some of these studies are reported here. 
While no general conclusions may be derived from them, they 
suggest certain possible lines for future experimentation and may 
serve as a guide in planning such experiments. 
A. 48/80 Toxicity in Mice 
The effect of certain histaminase inhibitors on the toxicity 
of this compound was tested in mice. This compound is the most 
poter1t hi stamine liberator available (Feldberg & Talesnik, 1953). 
rt was used as an approach to a possible role of histaminase in 
·the inactivation of liberated endogenous histamine. 48/80 was 
injected intravenously in doses of 0.05 mg./20 gms. which approxi-
mate the LD5o of this compound in mice as previously determined 
in this laboratory (Loew and Papacostas, 1955). His t aminase 
inhibitors were injected intraperi toneally one hour before ~. 8/80. 
The results are shown in Table 16. 
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Table 16 
Histaminase Inhibitors on the Intravenous Toxicity of 48L8o 
Compound Dose :· 'mM/20 gms. 
% Mortality 
Saline Difference 
Controls Treated From Controls 
1- A llylurea 0.01 70 60 -10 
Amino guanidine o.oo8 70 65 
- 5 
Hydroxylamine 0.001 60 60 0 
Piperazine 0.0005 60 20 -30 
Semicarbazide 0.001 6o 60 0 
" o.o1* 70 45 -25 
Thiosemicarbazide 0.001 70 80 +10 
" ..... These doses were estimated to be well below the lethal range 
(\-lhen given intra peritoneally) for each compound. In each case, 
twice the amount indicated produced definite toxic symptoms or 
deaths. 
48/80 was injected in doses of 0.05 mg/20 gms. {2.5 mg/kg), 
thirty minutes after intraperitoneal injections of the compound 
under test. 
Since imidazole was effective in potentiating histamine 
toxicity in mice, tests were made to determine the effect of this 
compound on the toxicity of 48/80. In these experiments, the 
intraperitoneal LD5o of 48/80 was determined simultaneously in 
control and imidazole treated animals. Two groups of 20 animals 
were used for each determination. Imidazole was injected subcu-
taneously one hour before 48/80 in doses corresponding to 1/2 its 
subcutaneous LD5o• The results are expressed in the usual fashion 
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as the 48/80 dose ratio ~or 50% mortality in control/treated 
animals (Table 17). 
Table 17 
In~luence o~ Imidazole on the Intraperi~oneal Toxicity o~ 
48/80 in Mice 
Dose in M/20 gm. 
48/80 LD5o mg/20 gm. 
48/80 Dose ratio 
and 95% con~. limits 
Controls 
0.11 
1.5 
(1.1 - 1.8) 
Imidazole-treated 
0.17 
It appears that imidazole does produce a small but signi~i­
cant potentiation o~ 48/80 toxicity in mice. This is probably 
related to the known hypotensive e~fect produced by either com-
pound which may be additive. other interpretations, however, are 
not excluded by the present results. 
B. Decrease in Rectal TesPerature in Mice, Rats, and Guinea Pigs 
This response to histamine may be taken as reflecting the 
well known e~~ect of this drug on peripheral vessels, ·i.e., a 
pronounced vasodilata~ton. It appears to be a relatively sensi-
tive response even in species which are considered as relatively 
insensitive to histamine (e.g., the mouse). 
In the present studies, rectal temperatures were measured 
0 thermoelectrically to the nearest 0.1 c. 
In a series o~ preliminary experiments in ~,there were 
marked ~luctuations in the readings from animal to animal but 
98 
there was often a tendency for the average rectal temperature of 
the group to fall, during the experimental period of about two 
hours. 
A definite response was produced with 1.0 mg./20 gms. i.p. 
histamine diphosphate, which amounts to a peak drop in rectal 
temperature of about 5°c. The effect was apparent 15 minutes 
after i.p. injection, and the peak was recorded at 60 minutes. 
The over-all response from injection to return to nearly control 
levels lasted for over two hours. These aspects of the response, 
i.e., sensitivity and prolonged reaction time, suggested that it 
may set optimal conditions for the study of possible potentiating 
effects by histaminase inhibitors. 
More extensive studies showed that the response to a dose 
was not reproducible from day to day. Furthermore, the dose-
response regression line was very flat with a regression coer.nui-
ent (slope) not significantly greater than zero (Table 18). Under 
such conditions, no valid tests can be made regarding potentiation 
(or antagonism) of histamine responses. There was some indication 
that a part of the variability between days could be ascribed to 
changes in room temperature. The degree of activity of the ex-
perimental animals seems to be very important in the variability 
of response. Perhaps the method may prove of some value under 
conditions where room temperature and activity of the experimental 
animals is controlled. 
Table 18 
Rectal Temperatures o~ Mice. Following Injections 
o~ Histamine (10 Animals per Dose) 
Dose: Histamine Diphosphate mg/20 gms. i.p. 
Time- Min. 
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saline 
controls 0.1 0.8 1.0 1.6 2.0 8.0 16.0 
Be~ ore 
injection 39±1 
A~ter 
injection 
10 40±1 39±1 38±2 37!2 36±1 39±2 38!2 37i2 
20 
40 
60 
120 
38±2 
38~2 
38!1 
38:!:1 
38±1 38±1 38±1 38±1 37±2 37±1 38±1 36±2 
38±1 38±1 37±1 38±1 37±1 36!1 37!1 37~1 37f2 
Similar studies in rats revealed a similar picture {Table 
-- . 
19). Here again, there was no signi~icant regression coe~cient 
(i.e., the slope o~ the dose-response regression line was not 
signi~icantly dif~erent than zero), and therefore the srune con-
siderations apply. 
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Table 19 
Rectal TemEeratures of Rats Following Injections 
' 
of Histamine {5 Animals Eer Dose) 
Time Dose: Histamine Diphosphate mg/100 gms. i.p. 
Min. Saline 
Controls 5 10 20 40 50 80 100 
Before 
injection 38:!:3 40!1 40:!:1 40:!:2 38±1 38±1 38±1 38±1 
After 
injection 
15 38±3 39f2 40:!:1 40!1 
30 38;!:3 40!1 39:!;1 40!2 36!1 37:!:1 37!1 36!1 
60 37±2 40±1 39±1 40:!:2 36±1 36±1 35fl 36!;1 
90 37+2 39f2 40±1 40:!:2 35+1 35+1 36+1 35-4-1 
- - - - -
The same effect of histamine was studied in a group of 5 
guinea ~· In this case, the effect was not very marked since 
doses of 5 mg./Kg. i.p. of histamine diphosphate produced a peak 
drop in rectal temperature of 1.5°c. This is probably the maximum 
dose that can be given with safety since the LD5o of histamine in 
this species has been determined as 8 mg./Kg. i.p. (See Figure 
5). Neyertheless, it may be used as an index of histamine effect 
in this animal for purposes of comparison with other species. 
c. Histamine Induced Gastric Secretion in Rats 
For these studie~ a species with low sensitivity to histamine 
was . chosen for reasons which have been discussed in the previous 
s ections. The animals were anesthetized with pentobarbital 
(6 mg/100 gms.) and an esophageal and pyloric ligation i~as per-
fo~med just previous to the injection of histamine. All injections 
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were made subcutaneously. Histamine was injected in doses of 
10 mg/100 gms. (of the diphosphate) one hour after pretreatment 
with histaminase inhibitors. The stomachs were removed at the 
end of 2 hours and, after injection of histamine, the volume was 
measured, and the free HCl acidity was determined by titrating 
against 0.02 or 0.01 N NaOH with Toppfer•s and phenophthalein 
as indicators. The total free HCl was ealculated from the titre.-
tion data. 
The results of these preliminary experiments are given in 
Table 20. They are based on 5 animals per group. In general, 
they show little or no effect of histaminase inhibitors on the 
gastric secretory response to histamine under these conditions. 
The results suggest that the effect of histaminase inhibitors on 
the secretory response to histamine in this species, if present 
at all, is not of a magnitude that can be readily demonstrated. 
Table 20 
Gastric Acidity and Volume in Response to Histamine and 
Histaminase Inhibitors in the Rat (5 Animals per Groum 
Pre-Treatment Histm. DiP04 Gastric Contents 
Dose mg/100 gms. Volume Total Free 
::_ ··mM/100 gms. in~ :MJ.. HCl IfiEq. 
None None 0.5:~;0.2 O.OOlt0.004 
None 1.0 1.7:!:0.3 0.036!0.006 
Amino guanidine 0.25 1.0 1.4:!:0·3 o.o26..,.o.oo6 
Imidazole 0.20 1.0 1.8;t0.4 o.o50tO.Ol 
Semicarbazide 0.05 1.0 0.9t0.3 o.o36so.o1 
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Another approach to the investigation of the role of histaminase on 
the in vivo inactivation of histamine would be to compare the magnitude 
and duration of the effects of histamine to tho~e of biologically active 
histamine analogues which are not attacked by histaminase. Alles et. al. (1943) 
reported tha t the alpha-methyl derivative of histamine is not attacked by hista-
minase while the 5-methyl derivative is attacked by this enzyme. The same 
autho r s compared the effects of these methyl derivatives to those of hista-
mine on a variety of biological responses. They found that the methyl 
derivatives had l/50 to 1/200 the biological activity of hi s tamine presumably 
because of a lower affinity for the histamine receptors. The biological effects 
of alpha-methyl-histamine were prolonged when compared to those of histamine. 
A similar prolongation was found with 5-methyl-histamine, thus making it 
unlikely that the prolongation of action was related to lack of inactivation 
by histaminase. It is of interest however to note that these authors found 
tha t the methyl derivatives of histamine were approximately twice as toxic 
in mice as was histamine. This was not the case regarding the toxicity of 
these compounds in guinea p igs where histamine was 50 times as toxic. 
In discus sing the action of his taminase inhibitors in vivo a comparison 
to better known examples of enzyme inhibition under similar test conditions 
may be advantageous. Two such enzyme systems may be considered: Acetylcholin-
esterase and amine oxidase. The former is known to hydrolyze acetylcholine 
(Ach) in vivo and to antagonize its pharmacological effects, while the latter 
is thought to be involved in the in vivo enzymatic oxidation of epinephrine 
and similar sympathomimetic amines (Blaschko et al. 1937, Schayer and Smiley 
1953). 
A comparison between histaminase and amine oxidase is of particular 
interest since the two enzymes are similar in many respects (Zeller 1951). 
The role of amine oxidase in the oxidation of sympathomimetic amines has not 
been settled however (~mrtin 1951) and therefore this en~e can not 
serve as a standard for comparison. Suffice it to say that amine 
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oxidase inhibitors, like histaminase inhibitors (and unlike Ach-esterase 
inhibitors), do not potentiate the pharmacological effects of epinephrine 
Hhen tested in the entire animal (Griesemer et a l.l953) or on isolated 
tis sues (Furchgott et al. 1955). 
It is often emphasized tha t the a ction of histami nase in vitro is 
slou compared to that of acetylcholinesterase and it i s suggested tha t 
simila r reaction rates may occur in vivo. This is . presented as an 
argtunent against the possibility that histarninase plays a role in the 
ina.ctiw .tion of h i stamine in vivo since it has been found repea tedly 
(e. g . 1.J"eiss, Rabb and Ellis, 1932) tha t the r a te of inactivation of injected 
histamine is very rapid (0.003 mg/min. in man). Such comparisons betvreen 
in vitro and in vivo r ates of enzymatic rea ctions and between different 
en~e-Gubstrate · systems have little if a~ validi~ when it is considered 
t hat the contribution of various factors existing under in .!!Y.g_ conditions 
is largely unkno;.m. Thus the in vitro rate of reaction of the li.ch-acetyl-
cholinesterase system is dependent not only on affinity constants but also 
on concentration of enzyme and substrate which under in~ conditions may 
a ct as limiting f a ctors (Augustinsson 1950). Similar considera tions apply 
to the histamine-his~se system especially since in this ca se the exa ct 
concentration of the enzyme present in _m vitro tests is unknovm. The 
subject of compari ng 1g_ vitro and in vivo e~tic a ctivities has been 
discussed extensively for the case of amine oxidase by Kohn (1937), who points 
out the l a ck of validity of such COI!l.parisons. 
From the above considera tions it is clear tha t no conclusi ve statements 
can be made regarding ,lli vivo r a tes of the histamine-hista..minase reaction 
ba sed only on r a tes observed ig vitro. 
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An important distinction between histaminase and Ach-esterase can be 
shown by considering their distribution in various tissues. Ach-esterase is 
found in muscle, nerve tissue and glands, i.e. in sites where Ach exerts its 
biological effects (Augustli~sson 1950, Nachmansohn and Wilson 1951). Thus it 
is conceivable tha t the Ach-acet,ylcholinestera se reaction proceeds simultan-
eously with the reaction of Ach Hi th cholinergic cell receptors. The same 
seems to hold true for amli~e oxidase (Burn 1952), although this enz,rme is 
also present in tissues in which epinephrine has no knoHD biological activity 
(Zeller 1951). By contrast, histaminase is found in tissues other than those 
in which hista~ine produces pharmacological effects: e.g. the histaminase of 
the intestine is located in the mucosa r ather than in the muscular l ayer; no 
histaminase exists in ~he stomach ~mere histamine exerts its effect on acid 
secretD1g cells (Rocha e Silva 1956). This distribution suggests tha t 
histaminase may not be involved in ti1e specific and immediate inactivation of 
hista.mine, but rather in the non-specific over all catabolism of histamine 
after an immediate inactivation has trucen place. 
If hista~inase does not play a role in the immediate inactivation of 
histamine li1 vivo some other agent must be involved D~ the rapid removal of 
injected histamine from the circulation. Parrot et al.(l951 1 1952, 1953) 
reported t hat this rapid inactivation may be brought about through the bindir€ 
of hista.mine by blood and tissue proteins, a phenomenon ~1hich they vrere able 
to demonstrate experimentally under in vitro conditions. More recent studies 
~aplan and Davis 1953) do not substantiate the conclusions of Parrot et al. 
It is tempting to suggest that the n runediate inactivation of histamine (and 
perhaps of other biologically active amines) is brought about ~~rough the 
combination of histamine with histamine receptors on effector cells thus 
rendering t..he amine unavailable. This may then be followed by a slm-r release 
of histami ne in the circulation (in accordance \dth phys:ico-chemical equilibrium), 
from •mere it is removed by various excretory or ca ta.bolic pathHay s, one of 
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which is oxidation by histaminase. 
It has been shown that the combination of hi.stamine rrith the effector 
cell receptors is in all probability a reversible one (Chen and Russell 1950). 
TI1e results of Pellerat (1945) se~n to support tl1e above hypothesis. He 
found that follm-ring treatment 1-rith antihista.miP..ics (which are known to act by 
combining witl1 histamine receptors) t he concentration of plasma histamine during 
anaphylaxis 1-ras several times the concentration obtained in the same co:ndi tion 
and in the absence of antihistaminics. This would suggest that, in the 
presence of an antihistaminic, some mechanism involved in the immedia te inacti-
vation of histamine was blocked. 
It is apparent that1his possibility of inactivation through binding with 
cell receptors deserves further consideration especially in connection with 
the question of the immediate inactivation of histamine and other biologica~ 
active compounds. 
In vierr of the above, it is of interest to consider the various results 
obtained in vivo •rith histaminase inhibitors and to inquire into the possible 
mode of action of these compounds rrhen they are found to act as histamine 
potentiators 1tnder certain conditions. 
Several lines of evidence indicate that the series of compounds under 
study are members of a group which apparently has certain stereo-chemical and/ or 
physico-ch~1ical similarities to histamine. Ma~ of them have been found to be 
strong histamine liberators (Macintosh and Paton 1949, Feldberg and Paton 1951, 
Mongar and Schild 1953). They are known to be potent and, to a certain extent, 
specific histamine.se inhibitors in vitro. In addition, some of our mm results, 
as well as those of others (Arunlaskana et al. 1954), suggest that in certain 
concentrations these compounds may act in an antihistaminic fashion. Furthe1~ore, 
they mny be considered as potentially histamine-like acting drugs since 
chemically they are me.t-nbers of a group '1-Thich has histamine-like activity. 
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The latter is in~erred from t he studies of Lee and Jones (1949), ~1o 
founLl tha t in a series of certain beta-runinoethyl-heterocyclic nitrogen 
compom1ds, an important requirement of hi stamine activity is the presence 
of the fragment - :N=6-CH2-CH2- NH2 or =N-C-cr-r2-CHrNH2 • In the present series 
all compounds contain one of the above f ragments . Sirnilarly, certain of our 
findings, such as intrinsic activity of some of the compounds on the cats ' 
blood pressure and r abbit i ntestine, may be i nterpr eted a s suggesting such 
a histrunine-like activity although this problem r equi res much further investi-
gation. 
In general, it appears from the over-all body of evidence that the 
compomrls under study have an affinity for histamine "receptors"* present 
in histaminase , on effector cells, and on the biochemical entities which 
hold histami ne i n the tissue bound form . 
It is possible that the relative affinities of these compounds f or each 
of the above three receptors may vary, since t here is often no correlation in 
t heir rela tive activities as histamD1aSe iTh~ibitors or histamine liberator s 
(Hangar and Schild 1953). \,lhile this may be so, not enough attention has been 
pai d to the distinction between affinity a nd intrinsi c activit~k ann it has 
not been shol-.'ll which one of these entities i s involved in the cases studied. 
A cor:J.pound may have a strong affi nity but no intrinsic activity. Thus 
a tropine has a s trong affinit-y for a cet ylcholDle smooth muscle ann gl and 
r eceptors. It is entir ely lackin~ any intrinsic activity i n contrast to 
par asympa thomimetic drugs which have appreciable intrinsic activities , even 
~*- Any biochemically or pharma cologically rea ctive site 1-rhich can be on an 
enzyme, on a cell or any chemical compmmd. The substance-receptor bond 
may be either combination of adsorption and it can be shown that the sa.me 
considera tions apply to bo~h. 
~k Affinity a1xl intrinsic activity are defined on page 22 . 
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though some of them may have lm-Ter a ffinity for t h e cell receptor comp2.red 
t o a tropine. A simila r sit1..w.tion hold s for histami ne receptors and antihi-
stami nics as uell as for certa i n ep i nephrine r e cep t ors and adrenergic blocking 
drugs . 
All of ~he above instances then may be considered as examples of a 
general phenomenon in which the present case of histamin.a.se i nhi b i t ors may 
be i ncl uded . The phenomenon is t ha t of competitive inhibition as appli ed to 
adsorption o.r combiTI...a.tion of t uo or more substances or rea ctive centers of a 
biological system. The theoretica l considera tions of t h i s phenomenon, as i t 
is ma11ifested in pharmacological a ctions , are given by Ari ens (1954, 1955), 
~rho also d iscusses a variety of examples . 
These considera tions suggest to us tl1e pos s ibility that the present 
series of compounds may a ct a s hiSUrnline potentiators in the r eported ca ses 
(11ongar an_d Schild 1951, Arunlaskana et al. 1954, Lindel and llestling 1951,), 
not by their ability to i nhibit histaminase, but due to their a ffinity for 
his tamine cell receptors• The theoretica l aspects of this possibil ity are 
discussed by Ariens. A similar example is given by Paton (1954), ~rho st2tes 
that a series of phenylalkyla:mmonium compounds can sensitize the receptor 
area to acetylcholDle without a ny interference with cholinesterase activity . 
Others (Eckert and Vari a nineu 194.9) have reported that Benadryl, a t doses 
near the lower limit of the antll1ista.minic effect, causes sensitization of 
the histrunine effects on blood pressure (dog, ca t) and guinea p i g ileum. 
In summary the experimental results of the entire s tudy indica te that 
.!!9.. ma ,jor potentiation of histamine effects occ1..u-s follmling treat.'llent with 
histaminase -inhibitors. This is true even in the ca se of species and tissues 
which are relatively insensitive to histrunine . Thus it would appear t hat the 
i nsensitivity of these tissues aTIJi species is not related to histaminase 
activity, suggesting tha t histaminase may not play a significant role in the 
1S8 
immediate biological inactivation of his tamine. 
Before the above st~gestion can be a ccepted, t he possibility must be 
considered t hat none of the compounds used had an affinity for histaminase 
strong enough to compete successftlily with hi stami ne under in vivo conditio1w. 
Evidence implyi ng that the compounds under study have an affini ty for 
h i stami ne receptors of effector cells was reviewed . I t vms then further 
suggested t hat the potenti ati ng activity of some of these compounds , parti-
cularly i n histamine sensitive tissues , may be related to an abi lity of the 
compound to sensitize the histarnine cell receptors in a manner analogous 
to the sensitization of a cetylcholine receptors proposed f or the act ion of 
certain phenylalkylaJrnnonium compottnds. 
IX GENERAL SUMHARY AND ABSTRACT 
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A. Introduction 
Compounds known to be histaminase inhibitors in vitr.o were 
studied for their ability to potentiate certain pharmacological 
effects of histamine. If histaminase plays a limiting role in 
the biological responses to histamine, histaminase inhibitors 
could serve as pharmacological tools in attempts to elucidate the 
problem of the possible physiological role of this naturally 
occuring and biologically highly active amine. 
B. Literature Review 
The available information on histamine metabolism, histamin-
ase (diamine oxidase), and histaminase inhibitors, was reviewed. 
The latter may be grouped into: 1) carbonyl reagents (semi-
carbazides, hydroxylamines, hydrazines), and 2) substituted or 
unsubsti tuted diamines and guanidines. Recent evidence(Schayer 
~ al. 1952, 1953) shows that aminoguanidine and other histamin-
ase i~hibitors block the major catabolic pathway of histamine in 
r ats and, to a certain extent, in guinea pigs. Iproniazid (a 
hydrazine), a potent inhibitor of amine oxidase, blocks the main 
catabolic pathway of histamine in mice and cats. These two 
metabolic pathways for histamine catabolism are distinct and 
apparently related to different enzyme systems. In very recent 
reports, histaminase inhibitors are said to act as specific 
potentiato!'s of histamine in the .responses of highly sensitive 
smooth muscle preparations (Arunlakshana et al • . 1954; Lindel & 
Westling, 1954; D.J. Smith, 1953). The reported de gree of 
potentiation is small, but it is not clear whether this is due 
to t he original high sensitivity of the tissue#) which may act as 
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a limiting factor. The published results do not establish that 
the reported effect is related to inhibition of histaminase, since 
the possibility is not excluded that the compounds may act as 
sensitizers of histamine receptors on smooth muscle for which 
they appear to have some affinity (Arlena, 1954)• 
C. Experimental 
A series of 20 compo"Lmds, kno~m to possess histaminase 
inhibitory activity in vitro, were tested ~A~their ability to 
potentiate histamine toxicity in rats. When given in doses of 
0.1 mM/100 gms., none of the compounds tested caused any major 
potentiation of histamine toxicity. Certain compounds caused a 
small,but significant,potentiation at this dose level. In 
addition, five compounds were tested at several dose levels and 
with several doses of histamine. The list included some of the 
better known and most potent in vitro inhibitors of histaminase: 
Aminoguanidine, imidazole, iproniazid, isoniazid, semicarbazide. 
Using the toxicity ratio {i.e., histamine LD5o in controls/hista-
mine LD5o in treated) as a sensitive index of the degree of 
potentiation, it was found that, with the exception of imidazole, 
none of the other compounds potentiated histamine toxicity in 
rats even with the maximum tolerated doses of. each compound {i.e . , 
1/2 the compounds' LD50 ). The potentiation produced by imidazole 
was not consistent in different experiments but, in general , the 
degree of potentiation was greater than would be expected from an 
additive effect of the toxicity of imidazole to that of histamine. 
It is therefore concluded that the effect of imidazole represents 
a true potentiation. The nature of this potentiation is however 
ill 
obscure and may not be related to histaminase inhibition. Con-
sideration or the drug ratios (i.e., molar dose or compound under 
test/molar dose or histamine) suggests that the tissue concentra-
tions or the compounds used (even with the maximum tolerated 
doses) may not have been surriciently high to compete advantageous-
ly with the relatively large doses or histamine. In conclusion, 
the results or the above experiments may be interpreted to mean 
t hat none of the inhibitors tested was sufriciently potent to 
manifest its effect in the presence of large doses of histamine 
under the experimental conditions employed. Alternatively, the 
results may be taken to indicate that histaminase plays no sig-
niricant role in the immediate inactivation or biologically 
active histamine in this species. 
Similarly, no major potentiation or histamine toxicity 
occurs in mice, rollowing treatment with various potent hista-
minase inhibitors. or the compounds tested, only imidazole 
caused a significant and consistent potentiation with sublethal 
doses. Iproniazid was without any effect in the doses tested. 
In all probability, the apparent small potentiation arter large 
doses of semicarbazide and stilbamidine was due to an added 
toxicity of the compound and can not be considered as true 
potentiation. In all respects, the results in mice were similar 
to those obtained in rats and may be interpreted in a similar 
manner. 
A limited study of four compounds on histamine toxicity in 
guinea ~ gave suggestive evidence that imidazole and semi-
carbazide, in molar doses several times the molar dose of 
histamine, were effective potentiators. Aminoguanidine seemed 
to potentiate in smaller doses and to inhibit in larger doses. 
In preliminary experiments, the potentiating effect of semi-
carbazide on histamine responses of the isolated guinea E.g_ 
i l eum was confirmed. Stilbamidine had no effect in similar 
tests. 
The characteristics of histamine responses were studied 
in isolated intestinal strips of the rabbit. In this tissue, the 
dose-response regression of histamine was found sufficiently 
sensitive to detect even small changes of the dose, having a 
precision i ndex (lambda) of less than 0.2. Aminoguanidine, 
i proni azid, i midazole and semicarbazide in doses of 10-6 to lo-3 
~1/cc had no potentiating effect on the histamine responses of 
this preparation.. Stilbamidine produced a small but significant 
potentiation, which could be related to histaminase inhibition. 
From the over-all results with rabbit intestine, it was con-
cluded that, in all probability, the relatively low sensitivity 
of this tissue to histamine is not related to a limiting role or 
h i staminase. 
The hypotensive response of the cat to histamine was studied 
in its relation to dose and basal blood pressure level. Dose-
r espons e regressions were obtained for the degree or hypotension, 
corrected :for basal blood pressure by covariance analysis, and 
were :found to have an index of precision (lambda) or 0.27. 
s everal o t her measures of response were analyzed but were :found 
to be of inferior precision. Aminoguanidine, hydroxylamine, 
i proniazid, and semicarbazide were studied for their ef:fects on 
the degree of hypotension induced by small doses of histamine. 
ll3 
Most tests were performed with doses of 0.01 to 0.1 mM/Kg. of the 
compound, corresponding to inhibitor/histamine molar ratios of 
3,000 to 30,000. No potentiating effects were noted with any of 
the above compounds in the doses used. Aminoguanidine and 
iproniazid, in larger doses, had an apparent "antihistarninic" 
effect. The lack of any potentiating effects may be attributed 
to the brevity of the response under study and may be taken to 
suggest that, in this case, histaminase plays no limiting role. 
Finally, preliminary studies on the effect of selected 
compounds on the toxicity of histamine liberator in mice (compound 
48/80), and the histamine induced gastric secretion in~­
thetized rats, indicated that histaminase inhibitors produce no 
marked changes in these effects. 
D. Sunnnary 
The experimental results of the entire study indicate that 
no major potentiation of histamine effects occurs following 
treatment with histaminase inhibitors. This is true even in the 
case of tissues and species which are relatively insensitive to 
histamine. Thus it would appear that the insensitivity of these 
tissues and species is not related to histaminase activity, 
suggesting that histaminase may not play a significant role in 
the immediate biological inactivation of histamine. Before this 
suggestion can be accepted, the possibility must be considered 
that none of the compounds used had an affinity for histaminase 
strong enough to compete successfully with histamine under in 
vivo conditions. Evidence implying that the compounds under 
study have an affinity for histamine receptors of effector cells 
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was reviewed. rt was suggested that the potentiating activity 
o£ some o£ these compounds, particularly in histamine sensitive 
tis sues, may be related to an ability o£ the compound to sensi-
tize the histamine cell receptors in a manner analogous to the 
sensitization o£ acetylcholine receptors proposed £or the action 
of certain phenylalkylammonium compounds (Paton, 1954)• 
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